



(51) International Patent Classification:

A61K 31/341 (2006.01) C07D 213/83 (2006.01)
A61K 31/35 (2006.01) C07D 295/12 (2006.01)
A61K 31/395 (2006.01) A61P 9/10 (2006.01)
A61K 31/44 (2006.01) A61P 27/00 (2006.01)

(21) International Application Number:

PCT/GB2013/052716

(22) International Filing Date:

17 October 2013 (17.10.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1218676.3 17 October 2012 (17.10.2012) GB
1218758.9 18 October 2012 (18.10.2012) GB
1304694.1 15 March 2013 (15.03.2013) GB

(71) Applicant: **THE UNIVERSITY OF BRISTOL** [GB/GB]; Senate House, Tyndall Avenue, Clifton, Clifton, Bristol Avon BS8 1TH (GB).

(72) Inventors: **HARPER, Steven, James**; Halewood Cottage, Tintern, Chepstow, Gwent NP16 6SX (GB). **BATES, David, Owen**; 38 Millicent Road, West Bridgford, Nottingham, Nottinghamshire NG2 7PZ (GB). **GAMMONS, Melissa**; Penverne, Mount George Road, Penelewey, Feock, Cornwall TR3 6QX (GB). **MORRIS, Jonathan**;

10/25-27 Kensington Road, Kensington, Sydney, New South Wales 2033 (AU).

(74) Agent: **HAMMOND, David, Matthew**; Haseltine Lake LLP, Redcliff Quay, 120 Redcliff Street, Bristol, Avon BS1 6HU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOUNDS USEFUL FOR TREATING OCULAR NEOVASCULAN




Figure 1

(57) Abstract: Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

COMPOUNDS USEFUL FOR TREATING OCULAR NEOVASCULAN

Field of the Invention

5 The present invention relates to anti-angiogenic treatments and compounds for use in anti-angiogenic treatments, particularly of conditions characterised by neovascularisation such as, for example, age-related macular degeneration.

The present invention also relates to treatments of hyperpermeability disorders and
10 compounds for use in treating hyperpermeability disorders.

The present invention also relates to treatments of neuropathic and neurodegenerative disorders and compounds for use in treating neuropathic and neurodegenerative disorders, such as, for example, Alzheimer's disease.

15 The present invention also relates to pain treatments, and compounds for use in treating pain.

The present invention also relates to methods of reducing the risk of pre-eclampsia, and compounds for use in such methods.

20

Background to the Invention

Age-related macular degeneration (AMD), a disease causing vision loss that affects the central area of the macula, is the leading cause of blindness in people over 50 years of age
25 (Bressler, 2004). Exudative AMD is the most severe form of AMD (Ferris *et al.*, 1984) primarily arising from the choroidal circulation beneath the macula and characterized by choroidal neovascularization (CNV). CNV, the abnormal growth of new vessels from the choroid into the retinal pigmented epithelium (RPE) (Patz *et al.*, 1977), is thought to lead to visual loss due to the leakage of blood and serous fluid beneath the RPE that eventually leads
30 to loss of photoreceptors, retinal detachment and dense macular scarring (Fine *et al.*, 2000; Campochiaro *et al.*, 2006). Vascular endothelial growth factor (VEGF), a key factor in angiogenesis and vascular leakage (Dvorak *et al.*, 1995) is up-regulated during the progression of CNV (D'Amore, 1994; Spilisbury *et al.*, 2000; Anderson *et al.*, 2002; Das *et al.*, 2003) and has become the lead therapeutic target for the treatment of exudative-AMD.

35

VEGF is a complex gene that is alternatively spliced to form a family of multiple isoforms (Leung *et al.*, 1989; Jingjing *et al.*, 1999), each isoform differing in biological property, activity and function (Houck *et al.*, 1991). Most cells commonly express isoforms VEGF₁₂₁, VEGF₁₆₅, and VEGF₁₈₉, whereas VEGF₁₄₅ and VEGF₂₀₆ are comparatively rare. The majority of VEGF isoforms contain exons 1-5 (the exception being VEGF₁₁₁ (Mineur *et al.*, 2007)) but differing portions of exons 6 and 7 that encode heparin sulphate (HS) binding domains. Alterations in the usage of these exons changes the biological properties of alternatively spliced isoforms such as their ability to bind to cell-surface heparan-sulfate proteoglycans and release angiogenic factors (Tischer *et al.*, 1991; Neufeld *et al.*, 1999).

In 2002 differential splicing of the eighth exon was demonstrated from a proximal splice site (PSS) to a distal splice site (DSS) 66 bases downstream (Bates *et al.*, 2002; Woolard *et al.*, 2004). Alternative splicing in this region generated a second family of isoforms (VEGF_{xxx}b), noted for their anti-angiogenic properties (Perrin *et al.*, 2005). WO 03/102105, the contents of which are incorporated herein by reference in its entirety describes the alternatively spliced isoforms, and their therapeutic significance.

During pathological angiogenesis pro-angiogenic isoforms are selectively upregulated (Bates *et al.*, 2002; Varey *et al.*, 2008; Pritchard-Jones *et al.*, 2007), suggesting VEGF_{xxx} and VEGF_{xxx}b may have separate regulatory pathways. These anti-angiogenic isoforms, such as VEGF₁₆₅b and VEGF₁₂₁b have been shown to be potently anti-angiogenic in animal models of retinal and choroidal neovascularisation, following intra-ocular injection (Hua *et al.* 2008), and result in both endothelial and retinal epithelial cell cytoprotection (Magnussen *et al.* 2010).

The first therapy to be FDA approved for the treatment of neovascular AMD in December 2004 was a VEGF₁₆₅, VEGF₁₈₉ and VEGF₂₀₆ specific aptamer, Pegaptanib Sodium (Macugen). During clinical trials pegaptanib dose-dependently reduced the risk of severe visual acuity loss and slowed the progression of neovascular AMD (Gragoudas *et al.*, 2004), but did not result in significant improvement in vision. In 2006 Ranibizumab (Lucentis), a novel humanized anti-VEGF antibody fragment, was FDA approved for the treatment of neovascular AMD. Its approval was based on the results of three clinical trials where, approximately 95% of patients treated monthly with Lucentis 0.5 mg maintained visual acuity (defined as the loss of <15 letters) and ≤40% improved vision (defined as the gain of ≥15 letters) at one year compared with 11% in the sham control treated group (Rosenfeld *et al.*, 2006; Brown *et al.*, 2006; Brown *et al.*, 2009). Current treatment regimes require Lucentis

administration by intra-ocular injection as often as monthly (Brown *et al.*, 2009; Schmidt-Erfuth *et al.*, 2011). Such intraocular injections result in increased intraocular pressure (Good *et al.*, 2010) and a risk, albeit minor, of endophthalmitis and other severe adverse effects (Jager *et al.*, 2004). Furthermore, bevacizumab (Avastin), an anti-VEGF antibody from which
5 Lucentis was derived, was shown to bind VEGF_{165b} with equal potency to VEGF₁₆₅, thus targeting both pro and anti-angiogenic VEGF isoforms (Varey *et al.* 2008).

As both the anti-angiogenic and angiogenic isoforms of VEGF are derived from the same gene, the control of isoform family is a result of the control of alternative splicing. We have
10 recently identified some of the pathways that control the splicing of VEGF at the proximal splice site, implicating the RNA binding protein SRSF1 (Nowak *et al.*, 2008; Amin *et al.*, 2011) and its kinase SRPK1 (Sanford *et al.*, 2005) as key requirements for the decision by cells to use the proximal splice site, and hence generate pro-angiogenic isoforms of VEGF (Nowak *et al.*, 2008; Nowak *et al.*, 2010). Knockdown of SRPK1 potently reduced VEGF
15 mediated angiogenesis *in vivo* in tumours and inhibition of SRPK1 and 2 reduced angiogenesis *in vivo* (Amin *et al.*, 2011).

WO 2008/11077, WO 2009/106855, WO 2010/058227, WO 2011/036429 and WO 2011/148200, the disclosures of which are incorporated herein by reference, describe
20 therapeutic and other physiological uses of agents which direct expression in favour of the VEGF_{xxx}b isoforms. SRPK inhibitors can in principle constitute such agents.

WO 2005/063293 describes a class of SRPK inhibitors including SRPIN340 and derivatives and analogues thereof.

25 The development of new agents for directing expression of VEGF_{xxx}b isoforms represents a new era not only in the treatment of, for example, neovascular AMD, but all other diseases in which VEGF_{xxx}b is implicated.

30 The present invention is based in part on new small molecule inhibitors targeting SRPK1 specifically for use as anti-angiogenic agents, neuroprotective agents, agents for use in treating or preventing hyperpermeability disorders, as agents for treating pain, and as agents for reducing the risk of, or treatment of, pre-eclampsia.


35 The present invention is also based at least in part on the surprising finding that low molecular weight compounds known to inhibit SRPK1 (e.g. SRPIN340 and derivatives and

analogues thereof) could be used topically or in dose-dependent manner to inhibit CNV progression.

Summary of the Invention

5

In a first aspect the invention provides a compound of Formula (I)



or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof;

10 wherein:

R¹ represents a hydrogen atom, a C₁₋₆ alkyl group which may have one or more substituent, a C₂₋₆ alkenyl group which may have one or more substituent, a C₂₋₆ alkynyl group which may have one or more substituent, a C₆₋₁₀ aryl group which may have one or more substituent, a halogen atom, a nitro group, a cyano group, an azido group, a hydroxy group, a C₁₋₆ alkoxy group which may have one or more substituent, a C₁₋₆ alkylthio group which may have one or more substituent, a C₁₋₆ alkylsulfonyl group which may have one or more substituent, a carboxyl group, a formyl group, a C₁₋₆ alkoxycarbonyl group which may have one or more substituent, an acyl group, an acylamino group, or a sulfamoyl group;

R² represents a hydrogen atom, a C₁₋₆ alkyl group which may have one or more substituent, or an aryl group which may have one or more substituent;

R³ represents a C₁₋₆ alkyl group which may have one or more substituent, a C₂₋₆ alkenyl group which may have one or more substituent, a C₆₋₁₀ aryl group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, an oxygen-containing heterocycle which may have one or more substituent, or a condensed aromatic heterocycle which may have one or more substituent;


R⁴ represents a hydrogen atom or a halogen atom;

Q represents -C(O)-, -C(S)-, -SO₂-, -C(S)NHC(O)-, -C(O)NHC(O)-, or C(O)NHC(S)-; and

W represents a hydrogen atom, amino, a C₁₋₆ alkyl group which may have one or more substituent, a C₆₋₁₀ aryl group which may have one or more substituent, a halogen atom, a

hydroxy group, a C₁₋₆ alkoxy group which may have one or more substituent, a C₁₋₆ alkylthio

group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, a condensed aromatic heterocycle which may have one or more substituent, or a group represented by the following formula (II):



5

wherein R^5 and R^6 are the same or different and each represents a hydrogen atom, a C_{1-6} alkyl group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, a condensed aromatic heterocycle which may have one or more substituent, an acyl group, or an acylamino group;

10 or the above R^5 and R^6 together with the adjacent nitrogen atom may form a heterocycle which may have one or more substituent, and the heterocycle may be a condensed aromatic heterocycle which may have one or more substituent;

or the above R^5 and R^6 may be a cycloalkylidene amino group which may have one or more substituent, or an aromatic condensed cycloalkylidene group which may have one or more substituent;

15

for use in dose-dependent treatment or prevention of ocular neovascularisation.

The dose dependency is preferably a sigmoidal efficacy/dose relationship, e.g. of the type illustrated in Figure 4 (left hand panel) of the accompanying drawings. The expression

20 “ocular neovascularisation” includes within its scope diseases and disorders characterised by ocular neovascularisation, including for example choroidal neovascularisation such as age-related macular degeneration. The term “ocular neovascularisation” also includes within its scope diseases and disorders characterized by retinal neovascularisation.

25 In a second aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof for use in the topical treatment or prevention of ocular neovascularisation.

The first and second aspects of the invention also provide respective methods of treatment or

30 prevention of ocular neovascularisation by administration of the compound of formula (I) to a subject in need of such treatment, and respective uses of a compound of formula (I) in the preparation of a medicament for treatment or prevention of ocular neovascularisation, as a dose-dependent treatment and/or as a topical treatment.

It is surprising and not expected from the prior art that the compounds used in the present invention enable dose-dependent treatment or prevention of ocular neovascularisation or topical treatment or prevention of ocular neovascularisation. Dose-dependent treatment is not inherently predictable, yet is highly desirable and beneficial for effective treatment.

5

The specific compounds of formula (I), and preferred or exemplified sub-classes of compounds of formula (I), as described in WO 2005/063293, and their pharmaceutically acceptable salts, solvates, hydrates and prodrugs, may be particularly mentioned for use in the present invention.

10

Further examples of the compounds of formula (I) that may be mentioned for use in the methods of the present invention are those in which R^3 is an oxygen-containing heterocycle which may have one or more substituent, or a 2- or 3- or 4-pyridyl group which may have one or more substituent. Preferred compounds include those in which R^3 is an oxygen-containing heterocycle substituted by a phenyl group or a 2- or 3- or 4-pyridyl group, which themselves may be further substituted as described herein. These compounds of formula (I) and their pharmaceutically acceptable salts, solvates, hydrates or prodrugs are new and as compounds *per se* (as well as their use in dose-dependent treatment or prevention of ocular neovascularisation and/or in the topical treatment or prevention of ocular neovascularisation) they constitute a further aspect of the present invention.

20

Pharmaceutical compositions comprising the novel compounds and the use of the novel compounds and pharmaceutical compositions comprising them in anti-angiogenic treatments (including the treatment and prevention of disorders and diseases characterised by abnormal or excessive angiogenesis), treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, treatment of non-inflammatory pain and methods of reducing the risk of pre-eclampsia constitute further aspects of the present invention.

25

In the novel compounds of formula (I) in which R^3 is an oxygen-containing heterocycle which may have one or more substituent, the R^3 group may, for example be a furanyl group optionally substituted by C_{1-6} alkyl, for example, methyl, for example 5-methyl-furan-2-yl, or a furanyl group optionally substituted by cyano, halo, nitro, formyl, 2- or 3- or 4-pyridyl or phenyl which each may have one or more substituents.

30

In the novel compounds of formula (I) in which R^3 is a 2- or 3- or 4-pyridyl group which may

have one or more substituent, the 2- or 3- or 4-pyridyl group which may have one or more substituent may, for example, be an unsubstituted 3-pyridyl group (namely, where the nitrogen heteroatom of the pyridyl group is *meta* to the Q group).

5 As preferred examples of the novel compounds of formula (I) there may be mentioned those in which the W is an amino group or a morpholinyl group which may have one or more substituent, more particularly an unsubstituted morpholin-4-yl group, or a 1-piperazinyl group which may have one or more substituent, for example a 4-methyl substituent or an alkylamino substituent, more particularly a 4-(dimethylamino)ethyl or a 4-(dimethylamino)propyl
10 substituent. In this group, there may be particularly mentioned the compounds wherein, in addition, R¹ is trifluoromethyl, R² and R⁴ are both H.

For use in the first and second aspects of the present invention there may be mentioned as particularly preferred (a) the above compounds of formula (I) in which R³ is an oxygen-
15 containing heterocycle which may have one or more substituent, for example a phenyl substituent or a 2- or 3- or 4-pyridyl substituent, or a phenyl substituent or a 2- or 3- or 4-pyridyl group which may have one or more substituent, (b) SRPIN340, the formula of which is shown in Figure 1 of the drawings, and (c) their pharmaceutically acceptable salts, solvates, hydrates or prodrugs. Examples of the compounds of formula (I) in which R³ is an oxygen-
20 containing heterocycle which may have one or more substituent, or a 2- or 3- or 4-pyridyl group which may have one or more substituent, include MVRL09 and MVRL10, the formulae of which are shown in Figure 1 of the drawings, and MVRL16, MVRL17, SPHINX9, SPHINX10, SPHINX12, SPHINX13 and SPHINX14, the formulae of which are shown in Table 1. For the avoidance of doubt, the compounds MVRL10, MVRL16 and
25 MVRL17 are also described as SPHINX, SPHINX6 and SPHINX7 respectively.

The compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates and prodrugs may be further characterized by one or more of the following features, which are, whether individually or in any combination, combinable with any of the examples and
30 preferences stated herein, or in WO 2005/063293, for the compounds:

1. R¹ may represent a trifluoromethyl group;

2. R³ may represent an oxygen-containing heterocycle or a 2- or 3- or 4-pyridyl group;

3. R³ may represent an oxygen-containing heterocycle substituted by a phenyl group or a 2- or

3- or 4-pyridyl group;

4. W may represent a 4-morpholino group which may have one or more substituents, or a 1-piperazinyl group which may have one or more substituents;

5

5. W may represent a 1-piperazinyl group or a 4-methyl-1-piperazinyl group or a 4-(2-(dimethylamino)ethyl)-1-piperazinyl group or a 4-(2-(dimethylamino)propyl)-1-piperazinyl group;

10 6. when R^1 is trifluoromethyl, $R^2 = R^4 = H$, R^3 is 4-(3-pyridyl)-furan-2-yl and Q is $-C(O)-$, then W is not the group represented by formula (II) wherein R^5 or R^6 is a C_{1-6} alkyl group substituted by amino or substituted amino; and

15 7. when $R^2 = R^4 = H$, R^3 is 4-pyridyl, and W is *N*-piperidinyl and Q is $-C(O)-$, then R^1 is not hydrogen.

The compounds represented by formula (I) include, for example:

20 (1) such compounds in which the above R^1 is a hydrogen atom, a C_{1-6} alkyl group, a halogenated C_{1-6} alkyl group, or a halogen atom;

(2) such compounds in which the above R^1 is a trifluoromethyl group;

25 (3) such compounds in which the above R^2 is a hydrogen atom or a C_{1-6} alkyl group;

(4) such compounds in which the above R^2 is a hydrogen atom;

30 (5) such compounds in which the above R^3 is a nitrogen-containing 5-to 10-membered heteroaryl ring having one or more substituents or an oxygen-containing 5- to 10-membered heteroaryl ring which may have substituents;

(6) such compounds in which the above R^3 is a pyridyl ring or a furan ring which may have one or more substituents;

35 (7) such compounds in which the above R^3 is a 2- or 3- or 4-pyridyl ring;

(8) such compounds in which the above R³ is a furan ring which may have one or more substituents;

5 (9) such compounds in which the above R³ is a furan ring substituted with a phenyl ring or a pyridyl ring;

(10) such compounds in which the above R⁴ is a hydrogen atom;

10 (11) such compounds in which the above Q is -C(O)- or -C(O)NHC(S)-, where C(O) means that an oxygen atom is linked with a carbon atom via a double bond, and C(S) means that a sulfur atom is linked with a carbon atom via a double bond;

(12) such compounds in which the above Q is -C(O)-;

15

(13) such compounds in which the above W is represented by formula (II) wherein R⁵ and R⁶, together with the adjacent nitrogen atom, form a heterocyclic group which may have substituents;

20 (14) such compounds in which the above W is a 4- to 8-membered heterocyclic group having one nitrogen atom, which may have a C₁₋₆ alkyl group as a substituent, a 4- to 8-membered heterocyclic group comprising one nitrogen atom and one oxygen atom, which may have a C₁₋₆ alkyl group as a substituent, or a 4- to 8-membered heterocyclic group comprising two nitrogen atoms which may have a C₁₋₆ alkyl group as a substituent;

25

(15) such compounds in which the above W is a 4- to 8-membered heterocyclic group comprising one or two nitrogen atoms, which may have a C₁₋₆ alkyl group as a substituent;

30 (16) such compounds in which the above W is morpholino group, which may have a C₁₋₆ alkyl group as a substituent;

(17) such compounds in which the above W is a piperidinyl group or a piperazinyl group, which may have a C₁₋₆ alkyl group as a substituent; and

35 (18) such compounds in which the above W is a piperazinyl group with a C₁₋₆ alkyl group as a substituent.

In the compounds described above, R¹ is preferred in the order of (1) to (2), with (2) more preferred. R² is preferred in the order of (3) to (4), with (4) more preferred. R³ is preferred in the order of (5) to (9), with (9) more preferred. Q is preferred in the order of (11) to (12), with
5 (12) more preferred. W is preferred in the order of (13) to (18), with (18) more preferred.

More preferable compounds are represented by the above formula (I), and comprise any combination of substituent types, each of which is selected from (1) to (2) for R¹, (3) to (4) for R², (5) to (9) for R³, (10) for R⁴, (11) to (12) for Q, or (13) to (18) for W.

10

Thus, particularly mentioned compounds are those of Formula (I) in which:

R¹ is a trifluoromethyl group;

R² and R⁴ are each hydrogen atoms;

15 R³ is a pyridyl ring or a furan ring, each of which may have one or more substituents;

Q is -C(O)-; and

W is a 4- to 8-membered heterocyclic group having one nitrogen atom, which may have one or more substituent, a 4- to 8-membered heterocyclic group comprising one nitrogen atom and one oxygen atom which may have one or more substituent, or a 4- to 8-membered
20 heterocyclic group comprising two nitrogen atoms which may have one or more substituent.

Within this class of compounds, more preferred compounds are those of Formula (I), in which:

25 R¹ is a trifluoromethyl group;


R² and R⁴ are each hydrogen atoms;

R³ is a pyridyl ring or a furan ring, each of which may have one or more substituents;

Q is -C(O)-; and

W is a morpholino group, a piperidinyl group or a piperazinyl group, each of which may have
30 one or more substituents.

Particularly mentioned compounds are those of Formula (Ia):



in which W is a 4- to 8-membered heterocyclic group having one nitrogen atom, which may have one or more substituent, a 4- to 8-membered heterocyclic group comprising one nitrogen atom and one oxygen atom which may have one or more substituent, or a 4- to 8-membered heterocyclic group comprising two nitrogen atoms which may have one or more substituent; and R₈ is hydrogen, a cyano group, a C₁₋₆ alkyl group, a phenyl group or a 2-, 3-, or 4- pyridyl ring. Substituents on the 4- to 8-membered heterocyclic groups defined by W may be those as defined elsewhere in connection with compounds of Formula (I).

Detailed Description of the Invention

Anti-angiogenic treatment

The anti-angiogenic treatment preferably includes the treatment or prevention of any disease or disorder associated with abnormal angiogenesis or abnormal over-production of pro-angiogenic VEGF isoforms (VEGF_{xxx}). Such diseases and disorders include, for example, vascular disease (e.g. vasoconstriction and disorders characterised by vasoconstriction, and cardiovascular disease), malignant and benign neoplasia (e.g. angiogenesis-dependent cancers, for example tumorous cancers), tumor metastasis, inflammatory disorders, diabetes, diabetic retinopathy and other complications of diabetes (e.g. diabetic neovascularisation), trachoma, retrolental hyperplasia, neovascular glaucoma, age-related macular degeneration, haemangioma, immune rejection of implanted corneal tissue, corneal angiogenesis associated with ocular injury or infection, Osler-Webber Syndrome, myocardial angiogenesis, wound granulation, telangiectasia, hemophiliac joints, angiofibroma, telangiectasia psoriasis scleroderma, pyogenic granuloma, coronary collaterals, ischemic limb angiogenesis, rubeosis, obesity, arthritis (e.g. rheumatoid arthritis), hematopoieses, vasculogenesis, gingivitis, atherosclerosis, endometriosis, neointimal hyperplasia, psoriasis, hirsutism and proliferative retinopathy. The anti-angiogenic treatment according to the present invention may also include non-therapeutic treatments performed on healthy subjects, for example to inhibit

vascular development for cosmetic purposes. For further details on diseases and disorders associated with abnormal angiogenesis, and on anti-angiogenic treatments, see WO 2008/110777, the contents of which are incorporated herein by reference.

5 *Microvascular hyperpermeability disorders, disorders of epithelial cell survival and disorders of fenestrations of epithelial filtration membranes*

The compounds of the present invention, as SRPK1 inhibitors, may also be used as therapeutic agents in treating other disorders in which the alternatively spliced VEGF_{xxx}b isoform has been implicated. For example, it has been shown in WO 2010/058227, the
10 contents of which are incorporated herein by reference, that VEGF_{xxx}b is active against a range of microvascular hyperpermeability disorders, disorders of epithelial cell survival and disorders of fenestrations of epithelial filtration membranes.

15 Microvascular hyperpermeability, disorders of regulation of the pro-angiogenic pro-permeability properties of VEGF_{xxx} isoforms, disorders of epithelial cell survival and permeability, and/or disorders in the nature (for example the number density and/or size) of fenestrations of epithelial filtration membranes underlie a number of serious medical conditions.

20

Examples of such conditions include, for example, proteinuria, uraemia, microalbuminuria, hypoalbuminemia, renal hyperfiltration, nephrotic syndrome, renal failure, pulmonary hypertension, capillary hyperpermeability, microaneurysms, oedema and vascular complications of diabetes.

25

Examples of such vascular complications of diabetes include, for example, diabetic retinopathy, both proliferative and non-proliferative, and diabetic nephropathy. Vascular complications of diabetes can be associated with either Type I or Type II diabetes.

30

The loss of proteins from the blood can lead to further complications, for example thromboses, especially thromboses in the brain, and susceptibility to infections. Loss of natural proteins from the blood can seriously impair the efficacy of cancer therapies.

35

The microvascular hyperpermeability disorder may particularly be a renal disorder, for example a permeability disorder of the GFB, for example a permeability disorder of the podocytes.

Examples of disorders where treatment to support epithelial cell survival would be effective are as follows:

5 acute pulmonary fibrotic disease, adult respiratory distress syndrome, adult respiratory distress syndrome, advanced cancer, allergic respiratory disease, alveolar injury, angiogenesis, arthritis, ascites, asthma, asthma or edema following burns, atherosclerosis, autoimmune diseases, bone resorption, bullous disorder associated with subepidermal blister formation including bullous pemphigoid, cardiovascular condition, certain kidney diseases
 10 associated with proliferation of glomerular or mesangial cells, chronic and allergic inflammation, chronic lung disease, chronic occlusive pulmonary disease, cirrhosis, corneal angiogenesis, corneal disease, coronary and cerebral collateral vascularization, coronary restenosis, damage following heart disease, dermatitis herpetiformis, diabetes, diabetic nephropathy, diabetic retinopathy, endotoxic shock, erythema multiforme, fibrosis,
 15 glomerular nephritis, glomerulonephritis, graft rejection, gram negative sepsis, hemangioma, hepatic cirrhosis, hepatic failure, Herpes Zoster, host-versus-graft reaction (ischemia reperfusion injury and allograft rejections of kidney, liver, heart, and skin), impaired wound healing in infection, infection by Herpes simplex, infection from human immunodeficiency virus (HIV), inflammation, cancer, inflammatory bowel disease (Crohn's disease and
 20 ulcerative colitis), inflammatory conditions, in-stent restenosis, in-stent stenosis, ischemia, ischemic retinal-vein occlusion, ischemic retinopathy, Kaposi's sarcoma, keloid, liver disease during acute inflammation, lung allograft rejection (obliterative bronchitis), lymphoid malignancy, macular degeneration retinopathy of prematurity, myelodysplastic syndromes, myocardial angiogenesis, neovascular glaucoma, non-insulin-dependent diabetes mellitus
 25 (NIDDM), obliterative bronchiolitis, ocular conditions or diseases, ocular diseases associated with retinal vessel proliferation, Osier-Weber-Rendu disease, osteoarthritis, ovarian hyperstimulation syndrome, Paget's disease, pancreatitis, pemphigoid, polycystic kidney disease, polyps, postmenopausal osteoporosis, preeclampsia, psoriasis, pulmonary edema, pulmonary fibrosis, pulmonary sarcoidosis, restenosis, restenosis, retinopathy including
 30 diabetic retinopathy, retinopathy of prematurity and age related macular degeneration; rheumatoid arthritis, rheumatoid arthritis, rubeosis, sarcoidosis, sepsis, stroke, synovitis, systemic lupus erythematosus, thyroiditis, thrombotic microangiopathy syndromes, transplant rejection, trauma, tumor-associated angiogenesis, vascular graft restenosis, vascular graft restenosis, von Hippel Lindau disease, wound healing.

35

The present invention may be used in the treatment of macular dystrophy. This includes: Stargardt disease/fundus flavimaculatus; Stargardt-like macular dystrophy; Stargardt-like macular dystrophy; Autosomal dominant “bull’s eye” macular dystrophy Best macular dystrophy; Adult vitelliform dystrophy; Pattern dystrophy; Doyne honeycomb retinal dystrophy; North Carolina macular dystrophy; Autosomal dominant macular dystrophy resembling MCDR1; North Carolina-like macular dystrophy associated with deafness; Progressive bifocal chorioretinal atrophy; Sorsby’s fundus dystrophy; Central areolar choroidal dystrophy; Dominant cystoid macular dystrophy; Juvenile retinoschisis; Occult Macular Dystrophy; Non-familial Occult Macular Dystrophy.

The disorder may particularly be a disorder of the retinal epithelium, such as geographic atrophy, or age related macular degeneration.

For further details on of microvascular hyperpermeability disorders, disorders of epithelial cell survival and disorders of fenestrations of epithelial filtration membranes, and the treatment thereof, see WO 2010/058227, the contents of which are incorporated herein by reference.

Neuropathic and neurodegenerative disorders

The compounds of the present invention, as SRPK1 inhibitors, may also be used as therapeutic agents in treating other disorders in which the alternatively spliced VEGF_{xxx}b isoform has been implicated. For example, it has been shown in WO 2009/106855, the contents of which are incorporated herein by reference, that VEGF_{xxx}b has neuroprotective and neuroregenerative effects.

Neuropathic disorders to be treated or prevented according to the present invention include neuropathic pain and diabetic and other neuropathies.

Neurodegenerative disorders to be treated or prevented according to the present invention include neurodegeneration of the cognitive and non-cognitive types, neuromuscular degeneration, motor-sensory neurodegeneration, ocular neurodegeneration.

The activities of the proteins of the VEGF_{xxx}b family are predicted to both actively prevent and actively reverse the conditions and disorders.

Furthermore, since mild cognitive dysfunction is often associated with the normal state in certain classes of healthy people, for example the aged, persons under stress, tired or exhausted persons, the present invention is also applicable to non-therapeutic treatments of healthy people to adjust or normalise their cognitive function and behaviour, including
 5 thinking, memory, learning, concentration and reasoning.

Still further, since neuroregeneration can assist in normalising brain neural networks in subjects having psychiatric or behavioural abnormalities, whether or not these are diagnosable as one or more recognised psychiatric condition, the present invention is also applicable to
 10 therapeutic treatment of persons having psychiatric disorders and to non-therapeutic treatment of physically healthy people to adjust their cognition and behaviour towards the normal state.

For example, the present invention provides for the treatment or prevention of: pain (for example, neuropathic pain), dementia, age-related cognitive impairment, Alzheimer's disease,
 15 senile dementia of the Alzheimer's type (SDAT), Lewy body dementia, vascular dementia, Parkinson's disease, postencephalitic Parkinsonism, depression, schizophrenia, muscular dystrophy including facioscapulohumeral muscular dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy syndrome (RSDSA),
 20 neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease, motor neurone diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis, postural hypotension, traumatic neuropathy or neurodegeneration e.g. following stroke or following an accident (for example, traumatic head injury or spinal cord injury), Batten's disease, Cockayne syndrome, Down syndrome, corticobasal ganglionic degeneration,
 25 multiple system atrophy, cerebral atrophy, olivopontocerebellar atrophy, dentatorubral atrophy, pallidolusian atrophy, spinobulbar atrophy, optic neuritis, sclerosing pan-encephalitis (SSPE), attention deficit disorder, post-viral encephalitis, post-poliomyelitis syndrome, Fahr's syndrome, Joubert syndrome, Guillain-Barre syndrome, lissencephaly, Moyamoya disease, neuronal migration disorders, autistic syndrome, polyglutamine disease,
 30 Niemann-Pick disease, progressive multifocal leukoencephalopathy, pseudotumor cerebri, Refsum disease, Zellweger syndrome, supranuclear palsy, Friedreich's ataxia, spinocerebellar ataxia type 2, Rhett syndrome, Shy-Drager syndrome, tuberous sclerosis, Pick's disease, chronic fatigue syndrome, neuropathies including hereditary neuropathy, diabetic neuropathy and mitotic neuropathy, prion-based neurodegeneration, including Creutzfeldt-Jakob disease
 35 (CJD), variant CJD, new variant CJD, bovine spongiform encephalopathy (BSE), GSS, FFI, kuru and Alper's syndrome, Joseph's disease, acute disseminated encephalomyelitis,

arachnoiditis, vascular lesions of the central nervous system, loss of extremity neuronal function, Charcot-Marie-Tooth disease, Krabbe's disease, leukodystrophies, susceptibility to heart failure, asthma, epilepsy, auditory neurodegeneration, macular degeneration, pigmentary retinitis and glaucoma-induced optic nerve degeneration.

5

Generally speaking, mental disorders are not diagnosed as "psychiatric disorders" unless the associated behaviours or thoughts cause significant distress to the individual or are disruptive of his or her everyday functioning. There is therefore a borderline between diagnosable disorders and similar, but less severe or disruptive, psychological functions the treatment of which should be considered as non-therapeutic (see below).

10

Examples of psychiatric disorders with which the present invention is concerned include, without limitation: anxiety disorders (for example, acute stress disorder, panic disorder, agoraphobia, social phobia, specific phobia, obsessive-compulsive disorder, sexual anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder and generalized anxiety disorder), childhood disorders (for example, attention-deficit hyperactivity disorder (ADHD), Asperger's disorder, autistic disorder, conduct disorder, oppositional defiant disorder, separation anxiety disorder and Tourette's disorder), eating disorders (for example, anorexia nervosa and bulimia nervosa), mood disorders (for example, depression, major depressive disorder, bipolar disorder (manic depression), seasonal affective disorder (SAD), cyclothymic disorder and dysthymic disorder), sleeping disorders, cognitive psychiatric disorders (for example, delirium, amnesic disorders), personality disorders (for example, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder, avoidant personality disorder, dependent personality disorder and obsessive-compulsive personality disorder), psychotic disorders (for example, schizophrenia, delusional disorder, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and shared psychotic disorder), and substance-related disorders (for example, alcohol dependence, amphetamine dependence, cannabis dependence, cocaine dependence, hallucinogen dependence, inhalant dependence, nicotine dependence, opioid dependence, phencyclidine dependence and sedative dependence).

15

20

25

30

For further details on neuropathic and neurodegenerative disorders, and the treatment thereof, see WO 2009/106855, the contents of which are incorporated herein by reference.

35

Treatment of pain

The compounds of the present invention, as SRPK1 inhibitors, may also be used as therapeutic agents in treating other disorders in which the alternatively spliced VEGF_{xxx}b isoform has been implicated. For example, it has been shown in WO 2011/148200, the contents of which are incorporated herein by reference, that VEGF_{xxx}b has an analgesic effect on VEGFR2-mediated non-inflammatory pain in mammals.

VEGFR2-mediated non-inflammatory pain to be treated or prevented according to the present invention includes non-inflammatory neuropathic and nociceptive pain where the VEGFR2 receptor is involved in the cause or transmission of the pain. For example, the compounds according to the present invention have activity against non-inflammatory allodynia and pain (antiallodynic and analgesic activity). Pain states of this type include chronic pain, whether of the intermittent or constant form. Such pain states may include, for example, low back pain, neuralgia, atypical pains such as atypical facial pain, pain exhibited post-surgery, post-injury (for example, after surgery or injury causing nerve damage) or in association with cancer or with cancer therapy such as cytotoxic or radiation therapy, or neuropathy associated with diabetes (diabetic neuropathy, insulin neuritis) or other systemic or autoimmune disease or pathology, or the treatment thereof, alcoholism or HIV infection, ageing associated neuropathy, or neuropathy of unknown origin.

The activities of the proteins of the VEGFR2 agonists, for example the VEGF_{xxx}b family, are predicted to both actively prevent and actively reverse VEGFR2-mediated non-inflammatory pain.

However, in view of the anti-angiogenic activity of the proteins of the VEGF_{xxx}b family, use of the compounds of the present invention will be restricted to pain in contexts where possible inhibition of angiogenesis would not be detrimental to the patient. In view of the likely pro-angiogenic activity of full VEGFR2 agonists, use of full VEGFR2 agonists will be restricted to pain in contexts where possible stimulation of angiogenesis would not be detrimental to the patient.

The compounds used in the present invention may be employed in association with one or more different pain treatment agent for the purpose of normalising the sensitivity towards pain of the subject treated (or being co-treated) with the said one or more different pain treatment agent. The term "normalising" means moving the subject's pain sensitivity towards

normal levels, and may include enhancement of the sensitivity if the one or more different pain treatment agent causes an excessive reduction in feeling or in sensitivity towards pain. The one or more different pain treatment agent may be selected from pain treatment agents currently known or yet to be devised. Such selection will be well within the skill of the person of ordinary skill in this art. Such combination treatments can enable fine control of pain sensitivity in subjects and minimisation of overall side effects according to the particular condition and needs of the subject.

For further details on pain, and the treatment thereof, see WO 2011/148200, the contents of which are incorporated herein by reference.

Reduction of Risk of Pre-Eclampsia

The compounds of the present invention, as SRPK1 inhibitors, may also be used as therapeutic agents in treating other disorders in which the alternatively spliced VEGF_{xxx}b isoform has been implicated. For example, it has been shown in WO 2011/036429, the contents of which are incorporated herein by reference, that reduced VEGF_{xxx}b levels in pregnant female mammals increase the risk of the female mammal developing pre-eclampsia. Thus, compounds of the present invention may be used to increase VEGF_{xxx}b levels in a pregnant female mammal so as to reduce the risk of pre-eclampsia the female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia.

Pre-eclampsia in humans can develop as early as 20 weeks of gestation. Pre-eclampsia that develops before about 34 weeks of gestation is normally referred to as “early pre-eclampsia” or “early-onset pre-eclampsia”. Pre-eclampsia that develops after about 34 weeks of gestation is normally referred to as “late pre-eclampsia” or “late-onset pre-eclampsia”.

In addition, pre-eclampsia can be categorised as “severe pre-eclampsia” according to criteria established by the United Kingdom Royal College of Obstetricians and Gynaecologists. Under these criteria, a patient with “severe pre-eclampsia” will have systolic blood pressure (BP) greater than 169 mmHg or diastolic BP greater than 109 mmHg with proteinuria greater than 1 g/24h; or will show occurrence of HELLP syndrome (haemolysis, elevated liver enzymes and low platelet count).

For further details on pre-eclampsia, and methods to reduce the risk of a pregnant female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia, see WO 2011/036429, the content of which are incorporated herein by reference.

5

Active compounds

Compounds of the present invention are as defined by Formula (I) and have been shown to be inhibitors of one or both of the kinases SRPK1, and SRPK2, and thus useful in treatments as described herein.

10

WO 2005/063293, incorporated herein by reference in its entirety, with particular reference to the explicitly exemplified compounds and preferred positions, describes known SRPK inhibitor SRPIN-1 (also referred to herein as SRPIN340) and its analogues as anti-viral agents.

15

The compounds of the present invention may be synthesised by any known method. Suitable methods as disclosed in WO 2005/063293 may be adapted as required.

20 *Co-administration*

The compounds of the present invention may, if desired, be co-administered with one or more additional active agent, for example one or more agent selected from, but not limited to, cholinesterase inhibitors, dopamine agonists (e.g. L-dopa), COMT inhibitors, MAO-B inhibitors, anti-cholinergics, acetylcholine agonists, serotonin agonists, AMPA receptor agonists, GABA receptor agonists, NMDA receptor agonists, β -adrenoceptor agonists, digoxin, dobutamine, anti-inflammatories, neurotrophic factors, statins, adenosine A2a receptor antagonists, aldose reductase inhibitors, immunomodulators, cannabinoid agonists, interferon or tricyclic anti-depressants.

25
30

Definitions

In the definition of formula (I) herein:

"C₁₋₆ alkyl group" refers to a linear or branched alkyl group comprising one to six carbon atoms, which is a monovalent group derived by removing an arbitrary hydrogen atom from an aliphatic hydrocarbon consisting of one to six carbons. Specifically, the C₁₋₆ alkyl group includes, for example, a methyl group, an ethyl group, a 1-propyl group, a 2-propyl group, a 2-methyl-1-propyl group, a 2-methyl-2-propyl group, a 1-butyl group, a 2-butyl group, a 1-pentyl group, a 2-pentyl group, a 3-pentyl group, a 2-methyl-1-butyl group, a 3-methyl-1-butyl group, a 2-methyl-2-butyl group, a 3-methyl-2-butyl group, a 2,2-dimethyl-1-propyl group, a 1-hexyl group, a 2-hexyl group, a 3-hexyl group, a 2-methyl-1-pentyl group, a 3-methyl-1-pentyl group, a 4-methyl-1-pentyl group, a 2-methyl-2-pentyl group, a 3-methyl-2-pentyl group, a 4-methyl-2-pentyl group, a 2-methyl-3-pentyl group, a 3-methyl-3-pentyl group, a 2,3-dimethyl-1-butyl group, a 3,3-dimethyl-1-butyl group, a 2,2-dimethyl-1-butyl group, a 2-ethyl-1-butyl group, a 3,3-dimethyl-2-butyl group, and a 2,3-dimethyl-2-butyl group;

"C₂₋₆ alkenyl group" refers to a linear or branched alkenyl group comprising two to six carbons. Specifically, the C₂₋₆ alkenyl group includes, for example, a vinyl group, an allyl group, a 1-propenyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a pentenyl group, and a hexenyl group;

"C₂₋₆ alkynyl group" refers to a linear or branched alkynyl group comprising two to six carbons. Specifically, the C₂₋₆ alkynyl group includes, for example, an ethynyl group, a 1-propynyl group, a 2-propynyl group, a butynyl group, a pentynyl group, and a hexynyl group.

"C₁₋₆ alkoxy group" refers to an oxy group to which the above-defined "C₁₋₆ alkyl group" is linked. Specifically, the C₁₋₆ alkoxy group includes, for example, a methoxy group, an ethoxy group, a 1-propyloxy group, a 2-propyloxy group, a 2-methyl-1-propyloxy group, a 2-methyl-2-propyloxy group, a 1-butyloxy group, a 2-butyloxy group, a 1-pentyloxy group, a 2-pentyloxy group, a 3-pentyloxy group, a 2-methyl-1-butyloxy group, a 3-methyl-1-butyloxy group, a 2-methyl-2-butyloxy group, a 3-methyl-2-butyloxy group, a 2,2-dimethyl-1-propyloxy group, a 1-hexyloxy group, a 2-hexyloxy group, a 3-hexyloxy group, a 2-methyl-1-pentyloxy group, a 3-methyl-1-pentyloxy group, a 4-methyl-1-pentyloxy group, a 2-methyl-2-pentyloxy group, a 3-methyl-2-pentyloxy group, a 4-methyl-2-pentyloxy group, a 2-methyl-3-pentyloxy group, a 3-methyl-3-pentyloxy group, a 2,3-dimethyl-1-butyloxy group, a 3,3-dimethyl-1-butyloxy group, a 2,2-dimethyl-1-butyloxy group, a 2-ethyl-1-butyloxy group, a 3,3-dimethyl-2-butyloxy group, and a 2,3-dimethyl-2-butyloxy group;

"C₁₋₆ alkylthio group" refers to a thio group to which the above-defined "C₁₋₆ alkyl group" is linked. Specifically, the "C₁₋₆ alkylthio group" includes, for example, a methylthio group, an ethylthio group, a 1-propylthio group, a 2-propylthio group, a butylthio group, and a
5 pentylthio group;

"C₁₋₆ alkoxy carbonyl group" refers to a carbonyl group to which the above-defined "C₁₋₆ alkoxy group" is linked. Specifically, the C₁₋₆ alkoxy carbonyl group includes, for example, a methoxy carbonyl group, an ethoxy carbonyl group, a 1-propyloxycarbonyl group, and a 2-
10 propyloxycarbonyl group;

"C₁₋₆ alkylsulfonyl group" refers to a sulfonyl group to which the above-defined "C₁₋₆ alkyl group" is linked. Specifically, the C₁₋₆ alkylsulfonyl group includes, for example, a methylsulfonyl group, an ethylsulfonyl group, a 1-propylsulfonyl group, and a 2-
15 propylsulfonyl group.

"halogen atom" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom;

"C₆₋₁₀ aryl group" refers to an aromatic cyclic hydrocarbon group comprising six to ten carbon
20 atoms. Specifically, the C₆₋₁₀ aryl group includes, for example, a phenyl group, a 1-naphthyl group, and a 2-naphthyl group;

"heterocycle" refers to an aromatic or non-aromatic ring that may comprise double bonds within the ring, wherein at least one, for example one or two, of the atoms constituting the
25 ring are heteroatoms;

"nitrogen-containing heterocycle" refers to an aromatic or non-aromatic ring that may comprise double bonds within the ring, wherein at least one, for example one or two, of the atoms constituting the ring are nitrogen atoms;
30

"oxygen-containing heterocycle" refers to an aromatic or non-aromatic ring that may comprise double bonds within the ring, wherein at least one, for example one or two, of the atoms constituting the ring are oxygen atoms;

35 "heteroatom" refers to a sulfur atom, an oxygen atom, or a nitrogen atom;

"nitrogen-containing 5- to 10-membered heteroaryl ring" refers to an aromatic ring in which five to ten atoms constitute the ring, wherein at least one of the atoms constituting the ring is a nitrogen atom, and one or more heteroatoms other than nitrogen atoms may further be comprised. Specifically, the nitrogen-containing 5- to 10-membered heteroaryl ring includes, for example, a pyridine ring, a pyrrole ring, an oxazole ring, an isoxazole ring, a thiazole ring, an isothiazole ring, an indole ring, an isoindole ring, an imidazole ring, a triazole ring, a pyrazole ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a quinoline ring, an isoquinoline ring, and a benzimidazole ring. The "5- to 10-membered heteroaryl ring" preferably includes a pyridine ring, a pyrrole ring, and an imidazole ring, and more preferably includes a pyridine ring;

"Nitrogen-containing 5- and 10-membered heteroaryl group" refers to a mono-or divalent group derived by removing one or two arbitrary hydrogen atoms from the above-defined "5- and 10-membered heteroaryl ring". Specifically, the nitrogen-containing 5- and 10-membered heteroaryl group includes, for example, a pyridyl group, a pyrrolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, an indolyl group, an isoindolyl group, an imidazolyl group, a triazolyl group, a pyrazolyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, a quinolyl group, an isoquinolyl group, and a benzimidazolyl group;

"Oxygen-containing 5- to 10-membered heteroaryl ring" refers to an aromatic ring in which five to ten atoms constitute the ring, wherein at least one of the atoms constituting the ring is an oxygen atom, and one or more heteroatoms other than oxygen atoms may further be comprised;

"4- to 8-membered heterocyclic ring" refers to a non-aromatic ring that meets the following definition:

1. four to eight atoms constitute the ring;
2. one or two of the atoms constituting the ring are heteroatoms;
3. one or two double bonds may be comprised in the ring;
4. one to three carbonyl groups may be comprised in the ring; and
5. the group is monocyclic.

The 4- to 8-membered heterocyclic ring is preferably a nitrogen-containing 4- to 8-membered heterocyclic ring that comprises nitrogen atoms as heteroatoms.

5 Specifically, the 4- to 8-membered heterocyclic ring includes, for example, an azetidine ring, a pyrrolidine ring, a piperidine ring, an azepane ring, an azocine ring, a furan ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholine ring, a piperazine ring, a thiazolidine ring, a dioxane ring, an imidazoline ring, and a thiazoline ring. The "4- to 8-membered heterocyclic ring" preferably includes a pyrrolidine ring, a piperidine ring, a
10 morpholine ring, and a piperazine ring;

"A 4- to 8-membered heterocyclic group" refers to a mono- or divalent group derived by removing one or two arbitrary hydrogen atoms from the above-defined "4- to 8-membered heterocyclic ring". Specifically, the 4- to 8-membered heterocyclic group includes, for
15 example, an azetidiny group, a pyrrolidinyl group, a piperidinyl group, an azepanyl group, an azocanyl group, a furyl group, a tetrahydropyranyl group, a morpholinyl group, a thiomorpholinyl group, a piperazinyl group, a thiazolidinyl group, a dioxanyl group, an imidazolyl group, and a thiazolyl group;

20 "Condensed aromatic heterocycle" refers to a ring structure in which the heterocyclic moiety is fused, for example ortho-condensed, with an aromatic ring, such as a benzene ring. The heterocyclic moiety is an above-defined heterocycle.

"Condensed aromatic heterocyclic group" refers to a ring structure in which the heterocyclic
25 moiety is fused, for example ortho-condensed, with an aromatic ring, such as benzene ring. The heterocyclic moiety is an above-defined heterocyclic group.

The condensed aromatic heterocyclic group includes, for example, an indolinyl group, an isoindolinyl group, and a 1,2,3,4-tetrahydroquinoline.

30

Herein, "halogenated C₁₋₆ alkyl group" refers to a group in which at least one arbitrary hydrogen atom in the above-defined "C₁₋₆ alkyl group" is replaced with an above-defined "halogen atom". The halogenated C₁₋₆ alkyl group includes, for example, a trifluoromethyl group, a difluoromethyl group, and a monofluoromethyl group.

35

Herein, the phrase "may have one or more substituent" means that a certain group or compound may optionally have an arbitrary selection or combination of one or more substituent at substitutable positions. Specifically, the substituents can include, for example, atoms or groups selected from one or more of: halogen, hydroxyl, mercapto, nitro, cyano, formyl, carboxyl, trifluoromethyl, trifluoromethoxy, amino, oxo, imino, C₁₋₆ alkyl (for example methyl), C₁₋₆ alkoxy (for example, methoxy), heteroaryl, phenyl, or phenyl or heteroaryl substituted by one or more of halogen, hydroxyl, mercapto, nitro, cyano, formyl, carboxyl, trifluoromethyl, trifluoromethoxy, amino, oxo, imino, C₁₋₆ alkyl (for example methyl) or C₁₋₆ alkoxy (for example, methoxy).

"Salt" is not particularly limited, so long as it is a pharmaceutical acceptable salt which is formed with a compound according to the present invention. Such salts include, for example, inorganic acid salts, organic salts, inorganic base salts, organic base salts, and acidic or basic amino acid salts. Examples of preferable inorganic acid salts include: hydrochloride, hydrobromate, sulfate, nitrate, and phosphate. Examples of preferable organic salts include: acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, and p-toluene sulfonate.

Examples of preferable inorganic base salts include: alkali metal salts, such as sodium salts and potassium salts; alkali earth metal salts, such as calcium salts and magnesium salts; aluminium salts; and ammonium salts. Examples of preferable organic base salts include: diethylamine salts, diethanol amine salts, meglumine salts, and N,N'-dibenzylethylenediamine salts.

Examples of preferable acidic amino acid salts include: aspartate and glutamate. Examples of preferable basic amino acid salts include: arginine salts, lysine salts, and ornithine salts.

When left in air, the compounds of the present invention sometimes absorb moisture, and are sometimes attached to absorbed water or converted to hydrates. Such hydrates are also included in the present invention.

Furthermore, compounds of the present invention are sometimes converted into solvates, absorbing some other solvents. Such solvates are also included in the present invention.

Any organic solvent may in principle be used to prepare a solvate of the compounds of the present invention.

A solvate can include also water together with the one or more organic solvent.

Thus, for example, the solvent may be selected from ketones, alcohols, ethers, esters,
5 aromatic solvents, and, where possible, mixtures thereof with each other, with other organic solvents and/or with water.

Pharmaceutically acceptable prodrug forms of the compounds of formula (I) may be used in the present invention. "Pharmaceutically acceptable prodrugs" means those prodrugs of the
10 compounds which are, within the scope of sound medical and veterinary judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds. The term "prodrug" means compounds that are rapidly transformed in vivo to
15 yield the parent compound of the above formula, for example by hydrolysis in blood. Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group. Because of the ease with which the metabolically cleavable groups of the compounds are cleaved in vivo, the compounds bearing such groups act as pro-drugs. A thorough discussion of prodrugs is provided in the following:
20 Design of Prodrugs, H. Bundgaard, ed. , Elsevier, 1985; Methods in Enzymology, K. Widder et al, Ed., Academic Press, 42, p. 309-396,1985; A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, ed. , Chapter 5; Design and Applications of Prodrugs p. 113-191, 1991 ; Advanced Drug Delivery Reviews, H. Bundgard, 8, p. 1-38, 1992; Journal of Pharmaceutical Sciences, 77, p. 285,1988 ; Chem.
25 Pharm. Bull. , N. Nakeya et al, 32, p. 692,1984 ; Pro-drugs as Novel Delivery Systems, T. Higuchi and V. Stella, Vol. 14 of the A. C. S. Symposium Series, and Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, 1987, which are incorporated herein by reference.

30 *Compositions and Administration*

The compound according to the present invention may be administered in the form of a composition comprising the active agent and any suitable additional component. The composition may, for example, be a pharmaceutical composition (medicament), suitably for
35 topical administration (e.g. as eyedrops or cream or lotion), or parenteral administration (e.g.

injection, implantation or infusion). The composition may alternatively, for example, be a foodstuff, food supplement, beverage or beverage supplement.

5 The term "pharmaceutical composition" or "medicament" in the context of this invention means a composition comprising an active agent and comprising additionally one or more pharmaceutically acceptable carriers. The composition may further contain ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, 10 lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms. The compositions may take the form, for example, of tablets, dragees, powders, elixirs, syrups, liquid preparations including suspensions, sprays, inhalants, tablets, lozenges, emulsions, solutions, cachets, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. 15 Techniques and formulations generally may be found in Remington, The Science and Practice of Pharmacy, Mack Publishing Co., Easton, PA, latest edition.

Liquid form preparations include solutions, suspensions, and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or topical 20 administration. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either topical, oral or parenteral administration. Such 25 liquid forms include solutions, suspensions, and emulsions. These particular solid form preparations are most conveniently provided in unit dose form and as such are used to provide a single liquid dosage unit. Alternately, sufficient solid may be provided so that after conversion to liquid form, multiple individual liquid doses may be obtained by measuring predetermined volumes of the liquid form preparation as with a syringe, teaspoon, or other 30 volumetric container or apparatus. The solid form preparations intended to be converted to liquid form may contain, in addition to the active material, flavourings, colourants, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like. The liquid utilized for preparing the liquid form preparation may be water, isotonic water, ethanol, glycerine, propylene glycol, and the like as well as mixtures thereof. 35 Naturally, the liquid utilized will be chosen with regard to the route of administration, for

example, liquid preparations containing large amounts of ethanol are not suitable for topical or parenteral use.

The composition may be in a formulation intended for topical application. The formulation may be a gelling formulation to control release and therefore availability of the active agent following topical application. The formulation may contain one or more gelling agents, for example hydroxypropyl methylcellulose. The formulation may contain one or more surfactants, for example a non-ionic liquid polymer, examples of which include Tyloxapol, and the Plurionics® poloxamers from BASF. The formulation may contain one or more solubilizers, for example dextrose or sorbitol. The formulation may contain one or more antimicrobial or antiseptic agents, for example benzalkonium chloride. The aforementioned named gelling agents, surfactants, solubilizers and antimicrobial agents are listed purely by way of example and it will be appreciated that other agents to perform these functions are known.

The dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with the smaller dosages which are less than the optimum dose of the compound. Thereafter the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The dosage regime for administration of the active agent may, for example, comprise a total dose of up to 1 µg, for example up to 500 ng, for example up to 50ng, for example less than 20ng of active agent in a dosing period ranging, for example, between 1 and 14 days. For example, a total dose of less than 18 ng, 17 ng, 16 ng, 15, ng, 14 ng, 13 ng, 12 ng, 11 ng or 10 ng may be administered.

The compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof may be administered in a therapeutically effective amount. A therapeutically effective amount of a compound of Formula (I) for topical administration for treatment of CNV may be at least about 5 µg/10 µl of delivery vehicle. Alternatively, a therapeutically effective amount may be at least about 100 µg/mL, for example at least about 200 µg/mL, at least about 300 µg/mL, at least about 400 µg/mL, at least about 500 µg/mL, at least about 600 µg/mL, at least about 700 µg/mL, at least about 800 µg/mL, at least about 900 µg/mL, or

at least about 1000 µg/mL, Alternatively, a therapeutically effective amount may be at least about 1 mg/mL, for example at least about 2 mg/mL, at least about 3 mg/mL, at least about 4 mg/mL, at least about 5 mg/mL. Alternatively, a therapeutically effective amount may be less than about 5 mg/mL, for example less than about 4 mg/mL, less than about 3 mg/mL, less than about 2 mg/mL, less than about 1 mg/mL. The therapeutically effective amount may be administered daily, for a dosing period ranging, for example, between 1 and 14 days. The therapeutically effective amount may be a total daily dosage which may be divided and administered in portions during the day, for example twice daily.

A therapeutically effective amount of a compound of Formula (I) for anti-angiogenic treatment of a mammalian subject, or for use in treating or preventing microvascular hyperpermeability disorders, or in regulating the pro-angiogenic pro-permeability properties of VEGF_{xxx} isoforms, or in supporting epithelial cell survival without increased permeability, or in reducing the nature (for example the number density and/or size) of fenestrations of epithelial filtration membranes, or for use in treating or preventing neuropathic and neurodegenerative disorders, or for use as a neuroprotective or neuroregenerative agent *in vivo* or *in vitro*, or for use in treating or preventing VEGFR2-mediated non-inflammatory pain, or for use in reducing the risk of a female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia may be calculated according to body mass of the subject to be treated, and may be at least about 20 mg/kg, for example at least about 30 mg/kg, at least about 40 mg/kg, at least about 50 mg/kg, at least about 60 mg/kg, at least about 70 mg/kg, at least about 80 mg/kg, at least about 90 mg/kg, at least about 100 mg/kg. Alternatively, the therapeutically effective amount may be less than about 100 mg/kg, for example less than about 90 mg/kg, less than about 80 mg/kg, less than about 70 mg/kg, less than about 60 mg/kg, less than about 50 mg/kg, less than about 40 mg/kg, less than about 30 mg/kg, or less than about 20 mg/kg, for example less than about 10 mg/kg, less than about 5 mg/kg.

“Treating or preventing”

The expression “treating or preventing” and analogous terms used herein refers to all forms of healthcare intended to remove or avoid the disorder or to relieve its symptoms, including preventive, curative and palliative care, as judged according to any of the tests available according to the prevailing medical and psychiatric practice. An intervention that aims with reasonable expectation to achieve a particular result but does not always do so is included

within the expression “treating or preventing”. An intervention that succeeds in slowing or halting progression of a disorder is included within the expression “treating or preventing”.

Certain neurological and psychiatric disorders are considered as “spectrum” conditions, in which individuals may exhibit some or all of a range of possible symptoms, or may exhibit only a mild form of the disorder. Furthermore, many neurological and psychiatric conditions are progressive, starting with relatively mildly abnormal symptoms and progressing to more severely abnormal symptoms. The present invention includes the treatment and prevention of all neurological and psychiatric conditions of whatever type and stage.

“Susceptible to”

The expression “susceptible to” and analogous terms used herein refers particularly to individuals at a higher than normal risk of developing a medical or psychiatric disorder, or a personality change, as assessed using the known risk factors for the individual or disorder. Such individuals may, for example, be categorised as having a substantial risk of developing one or more particular disorders or personality changes, to the extent that medication would be prescribed and/or special dietary, lifestyle or similar recommendations would be made to that individual.

“Non-therapeutic method”

The expression “non-therapeutic method” used herein refers particularly to an intervention performed on an individual who is neurologically or psychologically within the normal range, to normalise or enhance or improve a function of the neurological or psychological kind. A neurological function that may suitably be treated non-therapeutically may include, for example, cognition (including thinking, reasoning, memory, recall, imagining and learning), concentration and attention, particularly towards the milder end of the scale of conditions, and mild abnormal behavioural or personality traits. A psychological function that may suitably be treated non-therapeutically may include, for example, human behaviour, mood, personality and social function, for example grief, anxiety, depression, moodiness, moroseness, teenage moods, disrupted sleep patterns, vivid dreaming, nightmares, and sleepwalking.

There is a borderline between diagnosable neurological and psychiatric disorders and (non-diagnosable) neurological and psychological functions within the normal range. Therefore, in addition to the examples of neurological and psychological functions give above that are

5 treatable according to the non-therapeutic methods of the present invention, mild forms of neurological and psychiatric disorders, that are non-diagnosable because the associated behaviours or thoughts do not cause significant distress to the individual or are not disruptive of his or her everyday functioning, are also to be considered as conditions treatable non-therapeutically according to the present invention.

“Normalise”

10 The expression “normalise” and analogous terms used herein refers particularly to a physiological adjustment towards a condition characteristic of general normal neurological or psychiatric health, whether or not a condition is actually reached that would be characterised as normal.

Mammals

15 Besides being useful for human treatment, the present invention is also useful in a range of mammals. Such mammals include non-human primates (e.g. apes, monkeys and lemurs), for example in zoos, companion animals such as cats or dogs, working and sporting animals such as dogs, horses and ponies, farm animals, for example pigs, sheep, goats, deer, oxen and
20 cattle, and laboratory animals such as rodents (e.g. rabbits, rats, mice, hamsters, gerbils or guinea pigs).

Where the disorder or function to be treated is exclusive to humans, then it will be understood that the mammal to be treated is a human. The same applies respectively to any other
25 mammalian species if the disorder or function to be treated is exclusive to that species.

Brief Description of the Drawings

Embodiments of the present invention will now be described, purely by way of example, and
30 with reference to the accompanying drawings, in which:

Figure 1A shows the structures of three compounds which exhibit activity against SRPK1 and SRPK2;

35 Figures 1B and 1C show the activity of the compounds of Figure 1A against SRPK1 and SRPK2 respectively;

Figure 2A shows the effects of the compounds of Figure 1A on SRSF1 expression relative to a tubulin control in ARPE-19 cells;

5 Figure 2B shows the effects of the compounds of Figure 1A on expression of VEGF₁₆₅ mRNA isoforms relative to GAPDH in primary RPE cells;

Figure 2C shows the effects of the compounds of Figure 1A on VEGF expression relative to total protein;

10

Figure 2D shows the effects of the compounds of Figure 1A on the ratio of VEGF_{xxx_b}/Total VEGF expression;

15

Figure 3A shows the effects of the compounds of Figure 1A in a laser-induced mouse CNV model;

Figure 3B shows the effects of SRPIN340 on VEGF expression in a laser-induced rat CNV model, compared to the VEGF antibody G6-31;

20 Figure 3C shows the effects of SRPIN340 on VEGF expression in retinal protein from eyes treated with SRPIN340;

Figure 4A shows the dose-dependent nature of inhibition of laser-induced CNV by SRPIN340;

25

Figure 4B shows the half-life curve of SRPIN340 in the eye following intravitreal injection;

Figure 5A shows the effect of topically administered SRPIN340 drops on CNV lesion area;

30 Figure 5B shows the effect of topically administered SRPIN340 on VEGF₁₆₅ mRNA expression in the retina;

Figure 5C shows the half-life curve of SRPIN340 in the whole eye following topical administration;

35

Figure 5D shows the half-life curve of SRPIN340 in the posterior chamber of the eye following topical administration;

5 Figure 6 shows the ratio of pro to anti-VEGF isoforms in retinal protein following SRPIN340 treatment;

Figure 7 shows the level of SRPK1 inhibition of the compounds SPHINX, SPHINX6, SPHINX7 and SPHINX8 as defined in Formula (Ia) and Table 1 in an *in vitro* assay;

10 Figure 8 shows the level of SRPK1 inhibition of the compounds SPHINX, SPHINX12, SPHINX13 and SPHINX14 as defined in Formula (Ia) and Table 1 in an *in vitro* kinase assay ;

Figure 9A shows the effect of SPHINX6 and 7 on VEGF_{165b} RNA transcription;

15 Figure 9B shows the effect of SPHINX6 and 7 on VEGF_{165b} protein expression;

Figures 10A and 10B show that SPHINX7 inhibits SRSF1 phosphorylation induced by EGF activation;

20 Figure 11 shows that SPHINX7 inhibits angiogenesis in the eye as an eye drop. SRPIN340 and SPHINX7 significantly inhibited CNV formation. The IC₅₀ for SPHINX7 was 225ng/ml;

Figure 12 shows further data that demonstrates that SPHINX7 inhibits angiogenesis in the eye as an eye drop; and

25

Figure 13 demonstrates inhibition of prostate tumour growth by targeting SRPK1.

Methods

30 Cell culture

Primary human RPE isolations were performed on human donor globes obtained within 24 hours post-mortem from the Bristol Eye bank (Bristol Eye Hospital (BEH)). Retinas with choroid-RPE sheets were removed to a petri dish, finely chopped and digested in Dulbecco's Modified Eagle Medium (DMEM):F12(1:1)+GlutaMax (Gibco) supplemented with 0.3mg/ml collagenase for 15 minutes at 37°C. Digested choroid-RPE sheets were suspended in media

35

(DMEM:F12+GlutaMax) supplemented with 10% fetal bovine serum (FBS), 0.5% PenStrep (Invitrogen) and spun at 1500 rpm (251g) for 10 minutes to pellet cells. Pellets were resuspended in media supplemented with 25% FBS (Gibco), grown in cell culture flasks (Greiner) and split at 80% confluence. ARPE-19 (ATCC) cells were cultured in DMEM:F12
5 plus 10% FBS, split at 80% confluence.

In vitro Kinase Assay

Candidate compounds including MVRL09 , MVRL10 (SPHINX), MVRL16 (SPHINX6),
10 MVRL17 (SPHINX7), SPHINX8, SPHINX9, SPHINX10, SPHINX12, SPHINX13, SPHINX14 and SRPIN340 were screened by the Kinase-Glo assay (Promega; Koresawa and Okabe, 2004), the results of which are shown in Table 1. A reaction buffer containing 9.6mM MOPS pH7 and 0.2nM EDTA pH8 was added to 10µM SRSF1 RS peptide (NH₂-RSPSYGRSRSRSRSRSRSRSRSNSRSRSY-OH (SEQ ID NO: 1)) and 0.1µg of purified
15 SRPK1 kinase. Candidate compounds were serially diluted from 10µM-0.5nM and added to the reaction mixture, wells with omitted SRPK1 kinase and omitted compounds were also added as controls. All wells contained one percent DMSO. One micromolar ATP was added, wells minus ATP were used as background controls. The plate was then incubated at 30°C for 10 minutes. An equal volume of Kinase-Glo (Promega, 25µl) was added to each well and the
20 plate read for luminescence using an ARVO 5x (Perkin Elmer).

Pharmacological inhibitor treatments – SRPIN340, MVRL09 and MVRL10

SR protein phosphorylation inhibitors, SRPIN340 (N-[2-(1-piperidiny)-5-(trifluoromethyl)phenyl] isonicotinamide; Ascent Scientific, Cambridge), MVRL09 (N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide), MVRL10 (5-methyl-N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]furan-2-carb-oxamide) were used. Cells at ~60% confluence were serum starved for at least 12 hours and treated with five or 10µM compound inhibitors. Twenty-four hours later mRNA was extracted and 48 hours later protein
30 was extracted, for further analyses.

Semi-quantitative: reverse transcriptase (RT)-PCR for VEGF

Conventional PCR was used to detect VEGF₁₆₅ and VEGF_{165b} mRNA. Five-ten percent of the cDNA was added to a reaction mixture containing: 2x PCR Master Mix (Promega), primers (1µM each) complementary to exon7b (5'-GGC AGC TTG AGT TAA ACG AAC-3' (SEQ ID NO: 2)) and the 3'UTR of exon8b (5'-ATG GAT CCG TAT CAG TCT TTC CTG G-3' (SEQ ID NO: 3)) and DNase/RNase free water. All samples were run in parallel with negative controls (water and cDNA without reverse transcriptase (-RT)) and positive controls (VEGF₁₆₅ in a plasmid expression vector (pcDNA) and VEGF_{165b} pcDNA). The reaction mixture was thermo cycled (PCR Express, Thermo Electron Cooperation, Basingstoke) 30-35 times, denaturing at 95°C for 60 seconds, annealing at 55°C for 60 seconds and extending at 72°C for 60 seconds. PCR products were separated on 2.5% agarose gels containing 0.5µg/ml ethidium bromide (BioRad) and visualized under an ultraviolet transilluminator (BioRad).

Equal cDNA loading was determined by PCR with GAPDH primers (Forward: 5'-CAC CCA CTC CTC CAC CTT TGA C-3' (SEQ ID NO: 4); Reverse: 5'-GTC CAC CAC CCT GTT GCT GTA G-3' (SEQ ID NO: 5)). Primers result in one amplicon at ~112bp after thermo cycling 30 times, denaturing at 94°C for 45 seconds, annealing at 65°C for 45 seconds and extending at 72°C for 60 seconds.

PanVEGF and VEGF_{xxx}b enzyme-linked immunosorbent assay (ELISA).

One µg/ml pan-VEGF capture antibody (Duoset VEGF ELISA DY-293; R&D systems) was incubated overnight at room temperature. The plates were blocked (Superblock; Thermo Scientific) and serial dilutions of recombinant human (rh)VEGF₁₆₅ or rhVEGF_{165b} standards (ranging from 4ng/ml to 16.25pg/ml) were added, incubated alongside sample lysates, typically diluted 1:10. The plate was incubated for one hour at 37°C with shaking, washed and incubated with 100µl/well of either biotinylated goat anti-human VEGF (0.1µg/ml; R & D systems) or mouse anti-human VEGF_{165b} (0.25µg/ml) for one further hour at 37°C. After washing, 100µl/well of Horseradish Peroxidase (HRP)-conjugated streptavidin (1:200; R&D Systems) was added, and plates were left at room temperature for 20 minutes.

The plates were washed and colour change induced with substrate A and B (DY-999; R&D Systems) for 20mins under light protection. The reaction was stopped by addition of 100µl/well of 1M H₂SO₄ and the absorbance was read immediately in an ELISA plate reader

(Dynex Technologies Opsys MR system plate reader) at 450nm with a control reading at 570nm. Revelation Quicklink 4.25 software was also used to calculate a standard curve from mean absorbance values of standards enabling the estimation of VEGF concentration for each sample.

5

Western Blotting

Protein samples (30-50µg) were mixed with 1x sodium-dodecyl sulphate (SDS) loading buffer (100mM Tris-HCl, 4%SDS, 20% glycerol, 0.2% (w/v) bromophenol blue, and 5% final concentration 2-mercaptoethanol, pH6.8). To denature the protein, samples were boiled for five minutes at 100 °C.

Samples were subjected to polyacrylamide gel electrophoresis (PAGE) on a 12% SDS-PAGE gel at 90V in ice cold running buffer (25mM Tris-HCl, 250mM glycine, 0.1% SDS, pH8.3) for approximately 2.5 hours. The separated proteins were then electrophoretically blotted to a methanol-activated polyvinylidene fluoride (PVDF) membrane (Fisher Scientific) by wet transfer for two hours at 90V in transfer buffer (50mM Tris-HCl, 38mM glycine, 20% methanol, pH8.3). Membranes were incubated in blocking solution (2.5% non-fat dried milk in PBS/T or 5% BSA) with agitation at room temperature for 30 minutes, and then probed with the primary antibody overnight at 4 °C; rabbit polyclonal anti-VEGF-A (A20; sc-152, Santa Cruz) diluted 1:1000-1:200 in 2.5% non-fat dried milk PBS/T, VEGF_{xxx}b specific mouse monoclonal 56/1 (R&D Systems) diluted 1:1000 in 5%BSA PBS/T, mouse monoclonal SRSF1 (SF2/ASF) (96; sc-33652, Santa Cruz) diluted 1:1000 in 2.5% non-fat dried milk PBS/T and mouse monoclonal anti-SRPK1 (BD Biosciences, 611072) diluted 1:1000 in 5%BSA PBS/T. Membranes were then washed four times for 10 minutes each with TBS/0.3%T before incubation with secondary HRP-conjugated antibodies: goatmouse immunoglobulin G (IgG), goatarabbit IgG or rabbitagoat IgG (Pierce) diluted 1:10000 in 5% BSA PBS/T or 2.5% non-fat dried milk PBS/T, for 45 minutes at room temperature with agitation. The washes were repeated and the bands were detected using the Enhanced Chemoluminescence (ECL) SuperSignal West Femto Maximum Sensitivity Substrate kit (Pierce).

Pharmacological inhibitor treatments – SPHINX6 and SPHINX7

Primary human RPE cells were treated with increasing concentrations of SPHINX for 24 hours as described (Gammons et al *Invest. Ophthalmol. Vis. Sci.* 54(9) 6052-6062), followed

by RNA extraction, and RT-PCR carried out using primers that detect VEGF₁₆₅ (200bp) or VEGF_{165b} (130bp) as previously described (Bates et al 2002). Cells were treated with SPHINX6 and 7 and the PCR repeated.

- 5 Protein was extracted from RPE cells treated for 48 hours with SPHINXes and subjected to western blotting for VEGF_{165b} using anti-VEGF_{165b} antibody as previously described (Gammons et al *Invest. Ophthalmol. Vis. Sci.* 54(9) 6052-6062).

Inhibition of SRSF1 phosphorylation induced by EGF activation.

10

PC3 prostate cancer cells were treated with 10nM EGF in the presence of either DMSO (Vehicle), SPHINX, SRPIN340 or SPHINX7 at 10 μ M for 1 hr. Cells were lysed, and subjected to immunoblotting using an antibody to phosphorylated SR proteins (MAB104) and an antibody to tubulin as a loading control. Intensity was measured for SRSF1 and SRSF5
15 bands using ImageJ Intensity. Phosphorylation is calculated as the increase in intensity of the band over untreated relative to that for EGF with vehicle.

Laser lesion induction protocol

- Six to eight week-old C57/B6 mice (B&K Laboratories) and adult Norway-Brown rats
20 (Harlan Laboratories) were anaesthetized with an intraperitoneal injection of a mixture of 50mg/kg ketamine and 0.5mg/kg medetomidine. The pupils were dilated with 2.5% phenylephrine hydrochloride and 1% tropicamide. Four photocoagulation lesions were delivered with a krypton red laser (Mice: 250mW, 0.01s, 75 μ m, Rats: 200mW, 0.01s, 75 μ m, IRIS Medical 810nm Oculight Slx laser) between the retinal vessels in a peripapillary
25 distribution at a distance of 1-2 disc-diameters in each eye. Only laser lesions with a subretinal bubble at the time of treatment were included in the study. Immediately following laser photocoagulation the animals either received intravitreal injections in both eyes (day 0 and day 7), or given topical eye drops twice daily of 100 μ g /mL SRPIN340 or different doses of SPHINX7 (10 μ l volumes) in one eye and control vehicle in the other eye. Animals were
30 culled on either day 4 or day 14 and eyes were either unfixed for retinal dissection and protein extraction, or fixed and enucleated and choroids stained for isolectin-B4 and examined.

- During topical administration SRPIN340 or SPHINX7 were made up into a gel based drug delivery vehicle to aid duration of drug exposure to the eye (Doukas *et al.*, 2008), 0.05%
35 DMSO was used to dissolve SRPIN340 and was added to control vehicle .

In vivo prostate tumour study

1x10⁶ PC-3 RFP (red fluorescent protein) cells were injected surgically in the prostate gland of nude mice. The tumour volume was measured using an IVIS Lumina imaging system twice every week (expressed as total flux: photons/sec). Mice were treated three times a week with IP injections of either 20µg SPHINX, or vehicle, once tumours reached 2x10⁹ mean photons/sec. After 31 days, mice were culled and tumours extracted for further analysis. N=9, p<0.01, two way ANOVA.

10 Mass Spectrometry

A mass spectrometry based strategy was employed to determine the pharmacokinetics of SRPIN340 *in vivo*. Initially SRPIN340 and molecular derivative MVRL09 were serially diluted in water (initial stock dissolved in DMSO) from 100µg/ml to 0µg/ml and analysed. The chromatograms produced clear peaks at the expected molecular weights for SRPIN340 (349.1Da) and MVRL09 (351Da). The area under the peaks were integrated and plotted against concentration to confirm a linear response was observed. SRPIN340 was investigated in eye tissue following 20ng intravitreal injection and in eye tissue following a single topical application of 5µg. After a single administration mice were euthanized at time points 1, 4, 8, 24 and 48 hours. Samples, SRPIN340 (the analyte) and control treated, were homogenized and proteins were precipitated out of the samples with an equal volume (100µl) acetonitrile or acetone.

An internal standard of 100µg/ml MVRL09 was added to samples to account for any loss of samples during preparation. The solutions of 50% sample and 50% acetonitrile and 100µg/ml MVRL09 were centrifuged for 15 minutes at 4°C to pellet the proteins and the supernatant taken for analysis. Solutions were evaporated at 37°C for eight hours and resuspended in 30µl acetonitrile ready for injection and MALDI-TOF mass spectrometry analyser (Absciex). Each sample was run for five minutes and chromatograms produced. Standard curves were produced in both human plasma water matrices to determine concentration. Half life was calculated using Prism by fitting a one phase exponential decay to the sample concentrations from 1hr to 48hrs using a log plot.

Statistical Analyses

If not indicated otherwise, data are shown as mean \pm SEM. All data, graphs and statistical analyses were calculated with Microsoft Excel (Microsoft Office Software), GraphPad Prism (GraphPad Software Inc.) and Image J. All results were considered statistically significant at $p < 0.05$ (*), $p < 0.01$ (**) and $p < 0.001$ (***).

Results

10 Identification of novel SRPK1 inhibitors

To identify novel SRPK1 and highly related SRPK2 inhibitors, a range of inhibitors were screened in an *in vitro* kinase assay (Promega; Koresawa and Okabe, 2004). The previously identified SRPK inhibitor SRPIN340 (Fukuhara *et al.*, 2006) was used as a positive control for the identification of novel candidate compounds MVRL10 (5-methyl-N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl] furan-2-carboxamide) and MVRL09 (N-[2-(morpholin-4-yl)-5-(trifluoromethyl) phenyl]pyridine-3-carboxamide). The structural derivative SRPIN349 was used as a negative control (Figure 1). SRPIN349 has the same structure as SRPIN340 but with a hydrogen atom in place of the trifluoromethyl moiety. All three inhibitors showed some ability to inhibit the SRPK1 kinase, MVRL09 being the least effective with an IC_{50} greater than $10\mu M$. Both SRPIN340 and MVRL10 potently inhibited SRPK1 activity with IC_{50} values of $0.96\mu M$ and $0.85\mu M$, respectively (Figure 1B). The results gained in this assay are consistent with the published IC_{50} for SRPIN340 ($0.89\mu M$; Fukuhara *et al.*, 2006). Novel candidate compounds MVRL16 (SPHINX6), MVRL17 (SPHINX7) were also identified using the same *in vitro* kinase assay, exhibiting SRPK1 inhibition with IC_{50} values of $173nM$ and $54nM$ respectively (Figure 7). MVRL18 (SPHINX8), SPHINX9 and SPHINX10, in which the piperazine structure is missing exhibited no activity in the *in vitro* assay.

Subsequently the ability of these compounds to inhibit SRPK2 activity were investigated. SRPIN340 inhibited SRPK2 activity with an IC_{50} of $7.4\mu M$. MVRL09 showed no inhibition of SRPK2 and MVRL10 showed only 10% kinase inhibition at $10\mu M$ (Figure 1C). All three compounds preferentially target SRPK1 over SRPK2, but MVRL10 was the most specific, exhibiting a greater than 10 fold preference for SRPK1. A panel of 58 kinases was screened using microcalorimetry, and at $10\mu M$ a temperature shift of greater than $2^{\circ}C$ was seen only

for SRPK1 (9.82°), MSSK1A (7.93°C) and SRPK2 (3.5°C). All 55 other kinases had <2°C shift and 52 of them <1°C shift.

The SRPK inhibitors were tested in a series of *in vitro* assays to determine the effect of treatment on VEGF isoform expression. Initially the effect of compound treatment on SRPK1 and SRSF1 expression was determined. Previous publications had suggested SRSF1 phosphorylation by SRPK1 leads to the nuclear localisation of SRSF1 enabling its binding to VEGF pre mRNA where it can facilitate splicing (Nowak *et al.*, 2008; Nowak *et al.*, 2010; Amin *et al.*, 2011). We observed 10µM treatment of SRPIN340 and MVRL09 failed to affect SRPK1 expression even after six days of treatment in ARPE-19 cells. MVRL10 did appear to reduce SRPK1 expression suggesting it may alter the stability of the kinase (Figure 2A). Treatment of ARPE-19 cells with SRPIN340, MVRL09 and MVRL10 reduced expression of SRSF1 relative to a tubulin control after 72hours treatment times and extending up to six days (Figure 2A).

Inhibitor treatment for 24hours at 5µM altered the expression of VEGF₁₆₅ mRNA isoforms relative to GAPDH in primary RPE cells. All three inhibitors reduced the expression of VEGF₁₆₅ and MVRL09 induced clear expression of VEGF_{165b} (Figure 2B). We went onto investigate the effect of SRPK1 inhibition on VEGF protein expression. SRPIN340 and MVRL09 significantly reduced VEGF expression relative to total protein but MVRL10 failed to elicit any effect (Figure 2C). To determine whether MVRL10 altered the ratio of VEGF pro and anti-angiogenic isoforms we performed panVEGF and VEGF_{xxx}b specific ELISAs. All three inhibitors increased the ratio of VEGF_{xxx}b/Total VEGF with MVRL09 and MVRL10 being highly significant (p<0.01), suggesting SRPK1 inhibition reduces the expression of pro-angiogenic VEGF, promotes the expression of anti-angiogenic VEGF or a combination of both (figure 2D).

MVRL10 therefore appeared to be a relatively specific inhibitor of SRPK1. To determine whether SRPK1 inhibition could inhibit CNV in animal models we tested these compounds alongside each other in a laser-induced mouse CNV model. Two intravitreal injections of 10ng SRPIN340 and MVRL10 each significantly reduced neovascular area compared to control injected eyes to a similar extent (p<0.05, Figure 3A). To determine whether SRPIN340 could alter VEGF expression in the retina in which CNV was reduced, a rat model of laser induced CNV was used, as mouse monoclonal antibodies to VEGF isoforms cannot be easily used in mouse tissues, due to the potential detection of mouse IgG (which runs

similarly to VEGF). SRPIN340 was tested alongside the VEGF antibody, G6-31 (Roche). SRPIN340 injection (25ng) again significantly reduced the CNV area compared to saline injected controls ($p<0.05$). The VEGF antibody G6-31 resulted in a non-significant effect on CNV area in this rat model (Figure 3B), although it did result in a reduction in a mouse CNV model (Rennel et al, 2011).

Retinal protein from SRPIN340 and saline treated eyes 4 days after initial treatment was assessed for VEGF expression by western blot. A decrease in the expression of VEGF was observed in SRPIN340 treated eyes (Figure 3C). The expression of VEGF_{xxx}b isoforms was investigated using mouse monoclonal 56/1 antibody (R&D systems). No difference in the ratio of pro to anti-VEGF isoforms was observed in retinal protein following SRPIN340 treatment at this time point (Figure 6).

To determine the potency of SRPK1 inhibition by SRPIN340 at inhibiting laser-induced CNV in the mouse a dose-escalation study was performed. SRPIN340 dose-dependently reduced CNV area compared to control injected eyes with an EC_{50} of 1.28ng total injected dose (Figure 4A). We went on to determine pharmacokinetics of SRPIN340 in the eye following intravitreal injection. Injection of 20ng resulted in a relatively long and sustainable concentration of $>10\text{ng/ml}$ in the eye over a 2 day period. Curve fitting to the concentrations measured at 1, 4, 8 24 and 48 hours gave an estimated sustained half-life of 22hrs (Figure 4B).

Based on its low molecular weight and favourable drug qualities (MW349, LogP 3.68 and satisfies Lipinski's rule of 5), we hypothesized that SRPIN340 and related compounds may be capable of preventing VEGF mediated CNV when administered topically as an eye drop. We performed a dose response trial investigating SRPIN340 topical eye drops. SRPIN340 was dissolved in a previously described drug delivery vehicle (Doukas *et al.*, 2008) and administered twice daily. Fourteen days following laser insult choroids were fixed and flatmounted for isolectin staining and retinæ were extracted for RNA analysis.

Topical SRPIN340 drops dose dependently reduced CNV lesion area with an EC_{50} of 640ng total dose, 500 times the concentration required to achieve the same effect following SRPIN340 intravitreal injection (Figure 5A). Furthermore VEGF₁₆₅ mRNA expression in the retinæ was reduced following SRPIN340 treatment ($p=0.058$) (Figure 5B). To confirm SRPIN340 was detectable in the eye following topical administration mass spectrometry was performed. A single drop of 5 μg in 10 μl vehicle SRPIN340 was administered to one eye of

CD-1 mice and a control vehicle was administered to the other. After 1, 4, 8, 24 and 48 hours mice were culled and eye tissue from the anterior and posterior chamber of the eye was separately analysed for SRPIN340 expression. SRPIN340 was detected both in the whole eye and specifically in the posterior chamber. After 1 hour 3.5% of the total applied dose was detected in the eye (Figure 5C). In the posterior chamber, composed of retina, sclerochoroidal complex and residual vitreous, 0.15% of the applied dose was detected after 12 hours (Figure 5D). Exponential decay analysis using prism software generated an initial half-life in the posterior chamber of 35 minutes.

Discussion

We have used small molecule compound inhibitors of SRPK1 to reduce the expression of pro-angiogenic VEGF isoform VEGF₁₆₅ and inhibit CNV in vivo. We identified inhibitors that prevented SRPK1 phosphorylation of the SRSF1 RS domain serine residues *in vitro*. The interaction of SRSF1 with SRPK1 is well described in the literature (Aubol *et al.*, 2003; Velazquez-Dones *et al.*, 2005; Ngo *et al.*, 2005). SRSF1 is a protooncogene SR protein that regulates the alternative splicing of numerous genes, including VEGF (Sanford *et al.*, 2005). Here we have shown repeated administration of SRPK1 inhibitors to ARPE-19 cells reduced the expression of SRSF1 independent of SRPK1 expression suggesting phosphorylation of SRSF1 could be necessary for its cytoplasmic stability. Furthermore SRPK1 inhibitors SRPIN340 and MVRL09 reduced the expression VEGF₁₆₅ at RNA level and significantly reduced total VEGF expression at protein level. MVRL10 failed to affect VEGF protein levels, however further investigation into the expression ratio of pro- and anti-angiogenic VEGF isoforms showed MVRL10 significantly switched the ratio to favour the expression of anti-angiogenic VEGF isoforms. SPHINX7 at 100 nM has been shown to reduce the amount of VEGF₁₆₅ at RNA level (Figure 9A), increase VEGF_{165b} at protein level (Figure 9B), and inhibit SRSF1 phosphorylation at 10 μ M (Figures 10A and 10B). When tested *in vivo* in a mouse laser-induced CNV model all three inhibitors reduced the area of neovascular lesions with SPHINX7, SRPIN340 and MVRL10 (SPHINX) achieving significance.

Although a switch in VEGF splicing to anti-angiogenic VEGF isoforms was observed during SRPK1 inhibition in human primary RPE and ARPE-19 cell lines, detection of VEGF_{xxx}b isoforms remains to be definitively shown in mouse tissues. Both mRNA (detected by qPCR (Xu *et al* 2011, Zhao *et al* exp eye res, Caires *et al* Endocrinology) and protein (identified by Western blot (Zhao *et al*) have been described in mouse, but for both methods, the lack of stringent controls (excluding IgG contamination or cross amplification) could argue against

VEGF_{165b} expression (Harris et al). It has been suggested that the alternative splicing of VEGF transcripts increases during evolution with VEGF_{165b} expression being very low in normal mice increasing through rabbits and pigs to highest expression in primates (Xu et al 2011). Thus in the mouse model SRPK1 inhibitors may prevent CNV by reducing the expression of pro-angiogenic VEGF isoforms either by preventing the use of the proximal splice site, resulting in reduction of mature RNA, or through indirect alterations in transcriptional or translational regulation. Currently no investigations have identified the regulators of VEGF alternative splicing in mice. When tested in a laser-induced rat CNV model SRPIN340 (Fukuhara *et al.*, 2006) reduced CNV area and total VEGF protein expression. VEGF_{xxx}b expression was investigated in the rat retinae, VEGF_{xxx}b was expressed but no change in the expression of VEGF_{xxx}b isoforms was observed during SRPIN340 treatment compared to saline controls at that time point, suggesting in rodent models SRPK1 inhibition may be anti-angiogenic by reducing pro-angiogenic VEGF expression.

We went onto determine the EC₅₀ of SRPIN340 on CNV area in the mouse model. SRPIN340 produced at EC₅₀ of 1.28ng and the dose range of SRPIN340 used, 0.2–10 ng/eye, was similar to the dose of rhVEGF_{165b} previously used to inhibit CNV (Hua *et al.*, 2010). Hua and colleagues determined an effective rhVEGF_{165b} dose in humans of 3µg/eye, 1000- to 10-fold lower than ranibizumab or bevacizumab (Brown *et al.*, 2006). It is difficult to directly compare human specific Ranibizumab to the SRPIN340 efficacy data in mouse, compared to rhVEGF-A_{165b} SRPIN340 was 160 times less effective (Hua *et al.*, 2010) but required a dose 125 times less than pegaptanib in rodents (Ishida *et al.*, 2003). The data suggests SRPIN340 has the potential to achieve similar reductions in CNV as current treatment Ranibizumab at lower doses following intravitreal injection.

One of the drawbacks of Ranibizumab treatment is the need for monthly intraocular injections, thus we investigated whether SRPIN340 and SPHINX7 could potentially inhibit CNV following topical administration. Topical SRPIN340 significantly suppressed CNV in mice with an EC₅₀ of 3.187µg/ml, 500 times greater than injected SRPIN340. Pharmacokinetic analysis suggested 3.5% of the topically applied dose was detected in the eye after 1 hour reflecting previous estimations that due to poor ocular bioavailability only 5% of a topically applied drug will get into the eye (Geroski and Edelhauser, 2000). Furthermore, SRPIN340 was still detectable in the eye 48hours after a single topical administration but was not detected systemically. Despite only approximately 5% of applied SRPIN340 being likely of penetrating the eye the dose required to achieve 50% CNV inhibition using topical

SRPIN340 compares favourably to other topical therapies.

In 2008 Doukas and colleagues identified TG100801, an inactive pro-drug that generates TG100572 by de-esterification. TG100801 targets Src kinases and selected tyrosine receptor
5 kinases including VEGFR-1 and VEGFR-2, twice daily topical application of 1% but not 0.6% TG100801 significantly reduced CNV lesion area (Doukas *et al.*, 2008), however 0.01% SRPIN340 solution in the same drug delivery vehicle produced a significant inhibition of CNV area. To our knowledge SRPIN340 and SPHINX7 are the first topical compounds to alter the expression of pro-angiogenic VEGF isoforms. Following topical SRPIN340
10 treatment mouse retinae assessed for VEGF₁₆₅ expression showed a near significant reduction in VEGF₁₆₅ (p=0.058; n=3). VEGF₁₆₅, the more potently mitogenic VEGF isoform (Keyt *et al.*, 1996) is sufficient for physiological neovascularization during retinal development (Stalmans *et al.*, 2002). This study has focused on investigating VEGF₁₆₅ expression following SRPK1 inhibition; however, we predict the expression of other pro-angiogenic
15 VEGF isoforms such as VEGF₁₂₁ will also be reduced following SRPK1 inhibition. Indeed it has been shown that SRSF1 binds to human VEGF pre-mRNA in a region 35nt prior to the VEGF exon eight PSS, a splice site conserved both across species and by all pro-angiogenic VEGF isoforms (Amin *et al.*, 2011).

20 Treatment of induced prostate cancer in nude mice with IP injections of 20 µg SPHINX three times a week for 30 days led to a significant reduction in the tumour volume relative to a control saline injection (measured as total flux: photons/sec), demonstrating that the claimed compounds are also effective at inhibiting angiogenesis so can be used in anti-angiogenic treatment of mammalian subjects, for example treatment of cancer in mammalian subjects.

25 The data presented in this study suggests SRPK1 as a novel target for small molecular weight compound inhibitors in reducing pro-angiogenic VEGF mediated CNV associated with AMD. Furthermore we have shown that the compounds of the present invention are effective at reducing CNV following topical administration in mice, and for reducing tumour growth in
30 mice when injected.

















Name	W	R ₈	IC ₅₀ (nM) for SRPK1
SPHINX (MVRL10)		CH ₃	440
SPHINX6 (MVRL16)			177
SPHINX7 (MVRL17)			54.7
SPHINX8 (MVRL18)			9307
SPHINX9			>10000
SPHINX10			>10000
SPHINX12			367
SPHINX13			162
SPHINX14		CN	1268

Table 1 IC₅₀ data for compounds of Formula (Ia) tested in the SRPK1 inhibition assay

References

5

Bressler, S., Bressler, N. M., Clemons, T., Ferris, F. L., Milton, R. C., Klien, R., Klien, B. and Age-Related Eye Dis Study, G. (2004) 'Ocular risk factors for developing neovascular AMD in the fellow eyes of patients with unilateral neovascular AMD', *Investigative Ophthalmology*

& *Visual Science*, 45, U924-U924.

Ferris, F. L., Fine, S. L. and Hyman, L. (1984) 'Age-related macular degeneration and blindness due to neovascular maculopathy', *Archives of Ophthalmology*, 102(11), 1640-1642.

5

Patz, A., Fine, S. L., Finkelstein, D. and Yassur, Y. (1977) 'Diseases of macula - diagnosis and management of choroidal neovascularization', *Transactions American Academy of Ophthalmology and Otolaryngology*, 83(3), 468-475.

10 Fine, S. L., Berger, J. W., Maguire, M. G. and Ho, A. C. (2000) 'Drug therapy: Age-related macular degeneration', *New England Journal of Medicine*, 342(7), 483-492.

Campochiaro, P. A., Nguyen, Q. D., Shah, S. M., Klein, M. L., Holz, E., Frank, R. N., Saperstein, D. A., Gupta, A., Stout, J. T., Macko, J., DiBartolomeo, R. and Wei, L. L. (2006)
15 'Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial', *Human Gene Therapy*, 17(2), 167-176.

Dvorak, H. F., Brown, L. F., Detmar, M. and Dvorak, A. M. (1995) 'Vascular-permeability
20 factor vascular endothelial growth-factor, microvascular hyperpermeability, and angiogenesis', *American Journal of Pathology*, 146(5), 1029-1039.

D'Amore, P. A., Shima, D. T., Adamis, A. P., Yeo, K. T., Yeo, T. K., Allende, R. and Folkman, J. (1994) 'differential regulation of VEGF/VPF and basic FGF by hypoxia', *Faseb
25 Journal*, 8(4), A116-A116.

Spilisbury, K., Garrett, K. L., Shen, W. Y., Constable, I. J. and Rakoczy, P. E. (2000)
'Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment
epithelium leads to the development of choroidal neovascularization', *American Journal of
30 Pathology*, 157(1), 135-144.

Anderson, D. H., Mullins, R. F., Hageman, G. S. and Johnson, L. V. (2002) 'Perspective - A
role for local inflammation in the formation of drusen in the aging eye', *American Journal of
Ophthalmology*, 134(3), 411-431.

35

Das, A., Fanslow, W., Cerretti, D., Warren, E., Talarico, N. and McGuire, P. (2003)

'Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization', *Laboratory Investigation*, 83(11), 1637-1645.

5 Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. and Ferrara, N. (1989) 'Vascular endothelial growth-factor is a secreted angiogenic mitogen', *Science*, 246(4935), 1306-1309.

Jingjing, L., Xue, Y., Agarwal, N. and Roque, R. S. (1999) 'Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor', *Iovs*, 40(3), 752-759.

10 Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D. W. (1991) 'The vascular endothelial growth-factor family - identification of a 4th molecular-species and characterization of alternative splicing of rna', *Molecular Endocrinology*, 5(12), 1806-1814.

15 Mineur, P., Colige, A. C., Deroanne, C. F., Dubail, J., Kesteloot, F., Habraken, Y., Noel, A., Voo, S., Waltenberger, J., Lapiere, C. M., Nussgens, B. V. and Lambert, C. A. (2007) 'Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents', *Journal of Cell Biology*, 179(6), 1261-1273.

20 Tischer, E., Gospodarowicz, D., Mitchell, R., Silva, M., Schilling, J., Lau, K., Crisp, T., Fiddes, J. C. and Abraham, J. A. (1989) 'Vascular endothelial growth-factor - a new member of the platelet-derived growth-factor gene family', *Biochemical and Biophysical Research Communications*, 165(3), 1198-1206.

25 Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. (1999) 'Vascular endothelial growth factor (VEGF) and its receptors', *Faseb Journal*, 13(1), 9-22.

Bates, D. O., Cui, T. G., Doughty, J. M., Winkler, M., Sugiono, M., Shields, J. D., Peat, D., Gillatt, D. and Harper, S. J. (2002) 'VEGF(165)b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma', *Cancer Research*, 62(14), 4123-4131.

30 Woolard, J., Wang, W. Y., Bevan, H. S., Qiu, Y., Morbidelli, L., Pritchard-Jones, R. O., Cui, T. G., Sugiono, M., Waine, E., Perrin, R., Foster, R., Digby-Bell, J., Shields, J. D., Whittles, C. E., Mushens, R. E., Gillatt, D. A., Ziche, M., Harper, S. J. and Bates, D. O. (2004) 'VEGF(165)b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression', *Cancer Research*, 64(21), 7822-7835.

Perrin, R. M., Konopatskaya, O., Qiu, Y., Harper, S., Bates, D. O. and Churchill, A. J. (2005) 'Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor', *Diabetologia*, 48(11), 2422-2427.

5

Varey, A. H. R., Rennel, E. S., Qiu, Y., Bevan, H. S., Perrin, R. M., Raffy, S., Dixon, A. R., Paraskeva, C., Zaccheo, O., Hassan, A. B., Harper, S. J. and Bates, D. O. (2008) 'VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy', *British Journal of Cancer*, 98(8), 1366-1379.

10

Pritchard-Jones, R. O., Dunn, D. B. A., Qiu, Y., Varey, A. H. R., Orlando, A., Rigby, H., Harper, S. J. and Bates, D. O. (2007) 'Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma', *British Journal of Cancer*, 97(2), 223-230.

15

Hua, J., Spee, C., Kase, S., Rennel, E. S., Magnussen, A. L., Qiu, Y., Varey, A., Dhayade, S., Churchill, A. J., Harper, S. J., Bates, D. O. and Hinton, D. R. (2010) 'Recombinant Human VEGF(165)b Inhibits Experimental Choroidal Neovascularization', *Investigative Ophthalmology & Visual Science*, 51(8), 4282-4288.

20

Magnussen, A. L., Rennel, E. S., Hua, J., Bevan, H. S., Long, N. B., Lehlring, C., Gammons, M., Floege, J., Harper, S. J., Agostini, H. T., Bates, D. O. and Churchill, A. J. (2010) 'VEGF-A(165)b Is Cytoprotective and Antiangiogenic in the Retina', *Investigative Ophthalmology & Visual Science*, 51(8), 4273-4281.

25

Gragoudas, E. S. (2004) 'VEGF inhibition study in ocular neovascularization-1 (VISION-1): Efficacy results from phase II/III Macugen (TM) (Pegaptanib sodium) clinical trials', *Iovs*, 45(Suppl. 1), U924.

30

Rosenfeld, P. J., Rich, R. M. and Lalwani, G. A. (2006) 'Ranibizumab: Phase III clinical trial results', *Ophthalmology clinics of North America*, 19(3), 361-72.

Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., Schneider, S. and Grp, A. S. (2006) 'Ranibizumab versus verteporfin for neovascular age-related macular degeneration', *New England Journal of Medicine*, 355(14), 1432-1444.

35

Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P. and Ianchulev, T. (2009) 'Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study', *Ophthalmology*, 116(1), 57-65.

5

Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J.-F., Schlingemann, R. O., Axer-Siegel, R., Wiedemann, P., Simader, C., Gekkieva, M., Weichselberger, A. and Grp, E. S. (2011) 'Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study', *Ophthalmology*, 118(5).

10

Good, T. J. and Kahook, M. Y. (2010) 'The role of endothelin in the pathophysiology of glaucoma', *Expert Opinion on Therapeutic Targets*, 14(6), 647-654.

15

Jager, R. D., Aiello, L. P., Patel, S. C. and Cunningham, E. T. (2004) 'Risks of intravitreal injection: A comprehensive review', *Retina-the Journal of Retinal and Vitreous Diseases*, 24(5), 676-698.

20

Nowak, D. G., Amin, E. M., Rennel, E. S., Hoareau-Aveilla, C., Gammons, M., Damodoran, G., Hagiwara, M., Harper, S. J., Woolard, J., Ladomery, M. R. and Bates, D. O. (2010) 'Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms a novel therapeutic strategy for angiogenesis', *Journal of Biological Chemistry*, 285(8), 5532-5540.

25

Amin, E. M., Oltean, S., Hua, J., Gammons, M. V. R., Hamdollah-Zadeh, M., Welsh, G. I., Cheung, M.-K., Ni, L., Kase, S., Renne, E. S., Symonds, K. E., Nowak, D. G., Royer-Pokora, B., Saleem, M. A., Hagiwara, M., Schumacher, V. A., Harper, S. J., Hinton, D. R., Bates, D. O. and Ladomery, M. R. (2011) 'WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing', *Cancer Cell*, 20(6), 768-780.

30

Sanford, J. R., Ellis, J. D., Cazalla, D. and Caceres, J. F. (2005a) 'Reversible phosphorylation differentially affects nuclear and cytoplasmic functions of splicing factor 2/alternative splicing factor', *Proceedings of the National Academy of Sciences of the United States of America*, 102(42), 15042-15047.

35

Nowak, D. G., Woolard, J., Amin, E. M., Konopatskaya, O., Saleem, M. A., Churchill, A. J.,

Ladomery, M. R., Harper, S. J. and Bates, D. O. (2008) 'Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors', *Journal of Cell Science*, 121(20), 3487-3495.

- 5 Doukas, J., Mahesh, S., Umeda, N., Kachi, S., Akiyama, H., Yokoi, K., Cao, J., Chen, Z., Dellamary, L., Tam, B., Racanelli-Layton, A., Hood, J., Martin, M., Noronha, G., Soll, R. and Campochiaro, P. A. (2008) 'Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema', *Journal of Cellular Physiology*, 216(1), 29-37.

10

Fukuhara, T., Hosoya, T., Shimizu, S., Sumi, K., Oshiro, T., Yoshinaka, Y., Suzuki, M., Yamamoto, N., Herzenberg, L. A. and Hagiwara, M. (2006) 'Utilization of host SR protein kinases and RNA-splicing machinery during viral replication', *Proceedings of the National Academy of Sciences of the United States of America*, 103(30), 11329-11333.

15

Rennel, E. S., Regula, J. T., Harper, S. J., Thomas, M., Klein, C. and Bates, D. O. (2011) 'A Human Neutralizing Antibody Specific to Ang-2 Inhibits Ocular Angiogenesis', *Microcirculation*, 18(7).

- 20 Aubol, B. E., Chakrabarti, S., Ngo, J., Shaffer, J., Nolen, B., Fu, X. D., Ghosh, G. and Adams, J. A. (2003) 'Processive phosphorylation of alternative splicing factor/splicing factor 2', *Proceedings of the National Academy of Sciences of the United States of America*, 100(22), 12601-12606.

- 25 Velazquez-Dones, A., Hagopian, J. C., Ma, C. T., Zhong, X. Y., Zhou, H. L., Ghosh, G., Fu, X. D. and Adams, J. A. (2005) 'Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty', *Journal of Biological Chemistry*, 280(50), 41761-41768.

- 30 Ngo, J. C. K., Chakrabarti, S., Ding, J. H., Velazquez-Dones, A., Nolen, B., Aubol, B. E., Adams, J. A., Fu, X. D. and Ghosh, G. (2005) 'Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2', *Molecular Cell*, 20(1), 77-89.

35

Xu, J., Dou, T., Liu, C., Fu, M., Huang, Y., Gu, S., Zhou, Y. and Xie, Y. (2011) 'The evolution of alternative splicing exons in vascular endothelial growth factor A', *Gene*, 487(2).

Caires, K. C., de Avila, J. M., Cupp, A. S. and McLean, D. J. (2012) 'VEGFA Family Isoforms Regulate Spermatogonial Stem Cell Homeostasis in Vivo', *Endocrinology*, 153(2).

Zhao, M., Shi, X., Liang, J., Miao, Y., Xie, W., Zhang, Y. and Li, X. (2011) 'Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy', *Experimental Eye Research*, 93(6), 921-926.

Harris, S., Craze, M., Newton, J., Fisher, M., Shima, D. T., Tozer, G. M. and Kanthou, C. (2012) 'Do Anti-Angiogenic VEGF (VEGF_{xxx}b) Isoforms Exist? A Cautionary Tale', *Plos One*, 7(5).

McFee, R. M., Rozell, T. G. and Cupp, A. S. (2012) 'The balance of proangiogenic and antiangiogenic VEGFA isoforms regulate follicle development', *Cell and Tissue Research*, 349(3).

Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Amano, S., Ogura, Y., Hida, T., Oguchi, Y., Ambati, J., Miller, J. W., Gragoudas, E. S., Ng, Y. S., D'Amore, P. A., Shima, D. T. and Adamis, A. P. (2003) 'VEGF₍₁₆₄₎-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization', *Journal of Experimental Medicine*, 198(3), 483-489.

Geroski, D. H. and Edelhauser, H. F. (2000) 'Drug delivery for posterior segment eye disease', *Investigative Ophthalmology & Visual Science*, 41(5), 961-964.

Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H. and Ferrara, N. (1996) 'Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors - Generation of receptor-selective VEGF variants by site-directed mutagenesis', *Journal of Biological Chemistry*, 271(10), 5638-5646.

Stalmans, I., Ng, Y. S., Rohan, R., Fruttiger, M., Bouche, A., Yuce, A., Fujisawa, H., Hermans, B., Shani, M., Jansen, S., Hicklin, D., Anderson, D. J., Gardiner, T., Hammes, H. P., Moons, L., Dewerchin, M., Collen, D., Carmeliet, P. and D'Amore, P. A. (2002) 'Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms',


Journal of Clinical Investigation, 109(3).

Gammons, M.V., Dick, A.D., Harper, S.J., Bates, D. O. (2013) SRPK1 Inhibition Modulates VEGF Splicing to Reduce Pathological Neovascularization in a Rat Model of Retinopathy of Prematurity *Invest. Ophthalmol. Vis. Sci.* vol. 54(8) 5797-5806.

Gammons, M.V., Fedorov, O., Ivison, D., Du, C., Clark, T., Hopkins, C., Hagiwara, M., Dick, A.D., Cox, R., Harper, S.J., Hancox, J.C. and Bates, D.O. (2013) Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD *Invest. Ophthalmol. Vis. Sci.* 54(9) 6052-6062.

Claims

1. A compound of Formula (I)



or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof;

wherein:

- R^1 represents a hydrogen atom, a C_{1-6} alkyl group which may have one or more substituent, a C_{2-6} alkenyl group which may have one or more substituent, a C_{2-6} alkynyl group which may have one or more substituent, a C_{6-10} aryl group which may have one or more substituent, a halogen atom, a nitro group, a cyano group, an azido group, a hydroxy group, a C_{1-6} alkoxy group which may have one or more substituent, a C_{1-6} alkylthio group which may have one or more substituent, a C_{1-6} alkylsulfonyl group which may have one or more substituent, a carboxyl group, a formyl group, a C_{1-6} alkoxycarbonyl group which may have one or more substituent, an acyl group, an acylamino group, or a sulfamoyl group;


R^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have one or more substituent, or an aryl group which may have one or more substituent;

- R^3 represents a C_{1-6} alkyl group which may have one or more substituent, a C_{2-6} alkenyl group which may have one or more substituent, a C_{6-10} aryl group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, an oxygen-containing heterocycle which may have one or more substituent, or a condensed aromatic heterocycle which may have one or more substituent;

R^4 represents a hydrogen atom or a halogen atom;


- Q represents $-C(O)-$, $-C(S)-$, $-SO_2-$, $-C(S)NHC(O)-$, $-C(O)NHC(O)-$, or $C(O)NHC(S)-$; and W represents a hydrogen atom, amino, a C_{1-6} alkyl group which may have one or more substituent, a C_{6-10} aryl group which may have one or more substituent, a halogen atom, a hydroxy group, a C_{1-6} alkoxy group which may have one or more substituent, a C_{1-6} alkylthio group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, a condensed aromatic heterocycle which may have one or more substituent;

substituent, or a group represented by the following formula (II):



- 5 wherein R⁵ and R⁶ are the same or different and each represents a hydrogen atom, a C₁₋₆ alkyl group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, a condensed aromatic heterocycle which may have one or more substituent, an acyl group, or an acylamino group;
or the above R⁵ and R⁶ together with the adjacent nitrogen atom may form a heterocycle
10 which may have one or more substituent, and the heterocycle may be a condensed aromatic heterocycle which may have one or more substituent;
or the above R⁵ and R⁶ may be a cycloalkylidene amino group which may have one or more substituent, or an aromatic condensed cycloalkylidene group which may have one or more substituent;
15 for use in dose-dependent treatment or prevention of ocular neovascularisation.
2. A compound of Formula (I) as defined in claim 1, for use in the topical treatment or prevention of ocular neovascularisation.
- 20 3. A compound for use according to claim 2, wherein the topical treatment or prevention of ocular neovascularisation is dose-dependent treatment or prevention.
4. A compound for use according to claim 1, 2 or 3, wherein the ocular neovascularisation is choroidal neovascularisation, for example age-related macular
25 degeneration.
5. A compound for use according to claim 1, 2 or 3, wherein the ocular neovascularisation is retinal neovascularisation.

6. A compound of Formula (I):



5

or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof;

wherein:

R^1 represents a hydrogen atom, a C_{1-6} alkyl group which may have one or more substituent, a C_{2-6} alkenyl group which may have one or more substituent, a C_{2-6} alkynyl group which may have one or more substituent, a C_{6-10} aryl group which may have one or more substituent, a halogen atom, a nitro group, a cyano group, an azido group, a hydroxy group, a C_{1-6} alkoxy group which may have one or more substituent, a C_{1-6} alkylthio group which may have one or more substituent, a C_{1-6} alkylsulfonyl group which may have one or more substituent, a carboxyl group, a formyl group, a C_{1-6} alkoxycarbonyl group which may have one or more substituent, an acyl group, an acylamino group, or a sulfamoyl group;


R^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have one or more substituent, or an aryl group which may have one or more substituent;

R^3 represents an oxygen-containing heterocycle which may have one or more substituent, or a 2- or 3- or 4-pyridyl group which may have one or more substituent;

20 R^4 represents a hydrogen atom or a halogen atom;

Q represents $-C(O)-$, $-C(S)-$, $-SO_2-$, $-C(S)NHC(O)-$, $-C(O)NHC(O)-$, or $C(O)NHC(S)-$; and

W represents a hydrogen atom, amino, a C_{1-6} alkyl group which may have one or more substituent, a C_{6-10} aryl group which may have one or more substituent, a halogen atom, a hydroxy group, a C_{1-6} alkoxy group which may have one or more substituent, a C_{1-6} alkylthio group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, a condensed aromatic heterocycle which may have one or more substituent, or a group represented by the following formula (II):



wherein R⁵ and R⁶ are the same or different and each represents a hydrogen atom, a C₁₋₆ alkyl group which may have one or more substituent, a nitrogen-containing heterocycle which may have one or more substituent, a condensed aromatic heterocycle which may have one or more substituent, an acyl group, or an acylamino group;

or the above R⁵ and R⁶ together with the adjacent nitrogen atom may form a heterocycle which may have one or more substituent, and the heterocycle may be a condensed aromatic heterocycle which may have one or more substituent;

or the above R⁵ and R⁶ may be a cycloalkylidene amino group which may have one or more substituent, or an aromatic condensed cycloalkylidene group which may have one or more substituent.

7. A compound according to claim 6, for use in anti-angiogenic treatment of a mammalian subject.

8. A compound according to claim 6, for use in treating or preventing microvascular hyperpermeability disorders, or in regulating the pro-angiogenic pro-permeability properties of VEGF_{xxx} isoforms, or in supporting epithelial cell survival without increased permeability, or in reducing the nature (for example the number density and/or size) of fenestrations of epithelial filtration membranes.

9. A compound according to claim 6, for use in treating or preventing neuropathic and neurodegenerative disorders, or for use as a neuroprotective or neuroregenerative agent *in vivo* or *in vitro*.

10. A compound according to claim 6, for use in treating or preventing VEGFR2-mediated non-inflammatory pain.

11. A compound according to claim 6, for use in reducing the risk of a female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia.

12. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 6, optionally one or more other active ingredients and a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, optionally one or more other active ingredients and a pharmaceutically acceptable carrier, in a form suitable for intraocular injection.

5 14. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, optionally one or more other active ingredients and a pharmaceutically acceptable carrier, in a form suitable for topical administration to the eye.

10 15. The compound according to claim 6, or the compound for use according to any one of claims 1 to 5 or 7 to 11, or a pharmaceutical composition according to any one of claims 12 to 14, wherein R¹ represents a trifluoromethyl group.

15 16. The compound, the compound for use or the pharmaceutical composition according to claim 15, wherein R³ represents an oxygen-containing heterocycle or a 2- or 3- or 4-pyridyl group, each of which may have one or more substituents.

20 17. The compound, the compound for use or the pharmaceutical composition according to claim 16, wherein R³ represents an oxygen-containing heterocycle substituted by a phenyl group or a 2- or 3- or 4-pyridyl group.

18. The compound, the compound for use or the pharmaceutical composition according to any one of claims 15 to 17, wherein W represents a 4-morpholino group which may have one or more substituents, or a 1-piperazinyl group which may have one or more substituents.

25 19. The compound, the compound for use or the pharmaceutical composition according to any one of claims 15 to 18, wherein W represents a 1-piperazinyl group or a 4-methyl-1-piperazinyl group or a 4-(dimethylamino)ethyl-1-piperazinyl group or a 4-(dimethylamino)propyl-1-piperazinyl group.

1/15




Figure 1




Figure 2




Figure 3





Figure 4

5/15



6/15




Figure 6

7/15




Figure 7

8/15




Figure 8




Figure 9A

10/15




Figure 9B




Figure 10A

12/15




Figure 10B

13/15





Figure 11






Figure 13

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2013/052716

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/341 A61K31/35 A61K31/395 A61K31/44 C07D213/83
C07D295/12 A61P9/10 A61P27/00

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 712 242 A1 (HAGIWARA MASATOSHI [JP]) 18 October 2006 (2006-10-18)	6,12, 15-18
Y	paragraphs [0178] - [0189], [0208], [0211] - [0257]; examples 3-23 -----	6,12-19
X	WO 2009/020198 A1 (KINOPHARMA INC [JP]; ONOGI HIROSHI [JP]; HAGIWARA MASATOSHI [JP]; HOSO) 12 February 2009 (2009-02-12)	6,12, 15-18
Y	claim 1 page 69 - page 93; example all -----	6,12-19
X	EP 2 279 750 A1 (KINOPHARMA INC [JP]) 2 February 2011 (2011-02-02)	6,12, 15-18
Y	examples 3-21 claims 8,10,11 ----- -/--	6,12-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

3 February 2014

Date of mailing of the international search report

11/02/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Bonzano, Camilla

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2013/052716

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/080056 A2 (SLOAN KETTERING INST CANCER [US]; DJABALLAH HAKIM [US]; VARMUS HAROLD) 3 July 2008 (2008-07-03)	6,12, 15-18
Y	claim 86 -----	6,12-19
X	DE 11 87 420 B (SCHERING AG) 18 February 1965 (1965-02-18) column 1, line 15 column 2; example 1 -----	6,15-17
Y	WO 2011/134898 A1 (BOEHRINGER INGELHEIM INT [DE]; SOLCA FLAVIO [AT]; GUERTLER ULRICH [DE]) 3 November 2011 (2011-11-03) page 4, paragraph 2 - paragraph 5 -----	6,12-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2013/052716

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1712242	A1	18-10-2006	AU 2004308825 A1	14-07-2005
			CA 2551602 A1	14-07-2005
			CA 2801848 A1	14-07-2005
			CN 1921885 A	28-02-2007
			CN 101837125 A	22-09-2010
			EP 1712242 A1	18-10-2006
			EP 2666481 A2	27-11-2013
			JP 4771468 B2	14-09-2011
			JP 5227390 B2	03-07-2013
			JP 2011121948 A	23-06-2011
			KR 20070017314 A	09-02-2007
			US 2007135367 A1	14-06-2007
			US 2010016359 A1	21-01-2010
			US 2013079369 A1	28-03-2013
			WO 2005063293 A1	14-07-2005

WO 2009020198	A1	12-02-2009	JP 5349309 B2	20-11-2013
			WO 2009020198 A1	12-02-2009

EP 2279750	A1	02-02-2011	CN 102316900 A	11-01-2012
			EP 2279750 A1	02-02-2011
			KR 20100126544 A	01-12-2010
			US 2011059950 A1	10-03-2011
			WO 2009119167 A1	01-10-2009

WO 2008080056	A2	03-07-2008	AU 2007336781 A1	03-07-2008
			CA 2673299 A1	03-07-2008
			EP 2099770 A2	16-09-2009
			EP 2518063 A1	31-10-2012
			US 2010210649 A1	19-08-2010
			US 2013131062 A1	23-05-2013
			WO 2008080056 A2	03-07-2008

DE 1187420	B	18-02-1965	BE 649804 A	28-12-1964
			DE 1187420 B	18-02-1965
			GB 1052507 A	03-02-2014
			NL 6405293 A	28-12-1964
			US 3352663 A	14-11-1967

WO 2011134898	A1	03-11-2011	AU 2011246574 A1	27-09-2012
			CA 2793616 A1	03-11-2011
			CN 102869352 A	09-01-2013
			EA 201201464 A1	30-04-2013
			EP 2563348 A1	06-03-2013
			JP 2013525398 A	20-06-2013
			KR 20130069603 A	26-06-2013
			TW 201206441 A	16-02-2012
			US 2012107304 A1	03-05-2012
			US 2013289014 A1	31-10-2013
			WO 2011134898 A1	03-11-2011
